

Sr. no.	File No	Drug Name	Protocol	Applicant/Sponsor	Title	Phase	Sample size	Name of investigator and address	CT approval date
1	CT/196/11	Glimepride/Metformin	GLIME_R_05809	Sanofi Aventis	A multinational, open label, randomized, active-controlled, 3arm parallel group, 24 week study comparing the combination of glimepiride and metformin versus glimepiride and metformin alone in patients with Type 2 diabetes	III	Globally 400, India 200	<ol style="list-style-type: none"> <li>1. Dr. Parmesh Shamanna, Bangalore Cliniserach, 560043</li> <li>2. Dr. Prasanna Kumar, bangalore Diabetes Hospital, Bangalore</li> <li>3. Dr. sunil jain Totall Diabetes Hormone Institute, Indore</li> <li>4. Dr. sanjay Chatterjee, Apollo Gleneagles Hospitals, Kolkata</li> <li>5. Dr. Monica Gupta, samvedna Hospital, varanasi</li> <li>6. Dr. rajesh nair, Mar Augustine Golden Jubilee Hospital, Ernakulam, Kerala</li> <li>7. Dr. Pravin Supe, Super Hospital Institute of Excellance in Diabetes and Obesity, Nashik</li> <li>8. Dr. Mohan Magdum, Medipoint Hospitals Pvt. Ltd., Pune</li> </ol>	19-06-12
2	CT/205/11	Vildagliptin	CLAF237823156	Novartis	A 5 year study to compare the durability of glycemic control of a combination regimen with vildagliptin and metformin versus standard of care monotherapy with metformin , initiated in treatment naïve patients with type 2 diabetes mellitus	IV	Globally 4000, India 180	<ol style="list-style-type: none"> <li>1. Dr. Parmesh Shamanna, Bangalore Cliniserach, 560043</li> <li>2. Dr. Satish Kumar, Indraprastha apollo Hospitals, New Delhi</li> <li>3. Dr. Sunil Jain, Totall Diabetes Hormone Institute, Indore.</li> </ol>	14-06-12

3	CT/66/11	Tafenoquine	RM2010/000 52/01	GSK	A multicenter, double blind, randomised, parallel group, active controlled study to evaluate the efficacy, safety and tolerability of tafenoquine in subjects with Plasmodium vivax malaria	IIb/III	Globally 924 India 450	<ol style="list-style-type: none"> <li>1. Dr. B.H.K. Rao, Wenlock District Hospital, Mangalore</li> <li>2. Dr. D. K. Kochar, Kothari Medical and research Institute, Bikaner</li> <li>3. Dr. Nithya Gogtay, Seth G. S. Medical college and B.Y.L. Nair Hospital, Mumbai</li> <li>4. Dr. Ajay naranbhai Prajapati, Shradddha Hospital, ahmedabad</li> <li>5. Dr. Anup anvikar, National Institute of Malaria Research, New Delhi</li> <li>6. Dr. Sandeep Kumar Gupta, M.V. Hospital and Resaerch center, Lucknow</li> </ol>	7/3/2012
4	CT/38/12	NVA237	CNVA237A23 14	Novartis	A 12 week treatment, randomized, blinded, double-dummy, parallel group study to assess the efficacy, safety and tolerability of NVA237 (50µg o.d.) compared to tiotropium (18µg o.d.) in patients with chronic obstructive pulmonary disease (COPD)	III	Globally 660 India 110	<ol style="list-style-type: none"> <li>1. Dr. J. C. Suri, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi</li> <li>2. Dr. Pattabhiraman, Kovai Medical Center and Hospital, Coimbatore</li> <li>3. Dr. Deepak talwar, Metro Multispecificity Hospital, Noida</li> </ol>	30-07-12

5	CT/37/12	CP-690,550	A3921095	Pfizer	A multicenter, randomized, double-blind, placebo controlled, parallel group study of oral CP-690550 as an induction therapy in subjects with moderate to severe ulcerative colitis	III	Globally 545, India 60	<p>1. Dr. Abraham Koshy, Lakeshore Hospital &amp; Research Centre, Kochi, Kerala-682040.</p> <p>2. Dr. Rupesh Mehta, Mehta Hospital, 57, Brahmin Mitra Mandal Society, Paldi, Ahmedabad-380006.</p> <p>3. Dr. Murali Krishna Palakurthy, Manikya Institute Of Gastroenterology and Hepatology, MVV Chambers, KGH OP Bus Stop, Maharanipecta, Visakhapatnam, Andhra Pradesh-530002.</p> <p>4. Dr. Prabhakar Boddu, Gastroenterology Research Unit GE Department, Osmania General Hospital, Afzalgunj, Hyderabad – 500012.</p> <p>5. Dr. Mohan V. G. Prasad, VGM Hospital, No 2100, Trichy Road, Rajalakshmi Mills Stop, Coimbatore-641005.</p> <p>6. Dr. Vishwanath B Tantry, Manipal Centre for Clinical Research, 7th Floor, KMC Hospital, Attavar, Mangalore-575001.</p> <p>7. Dr. Hasmukh Vora, Sushrusha Hospital, Opp Sardar Patel Seva Samaj Hall, In Lane Opp. Navrangpura Telephone Exchange, Navarangpura, Ahmedabad - 380009.</p>	7/12/2012
---	----------	------------	----------	--------	--	-----	------------------------	---	-----------

6	CT/22/12	CP-690,550	A3921084	Pfizer	A randomized, double-blind, placebo-controlled parallel group multicentre study to investigate the safety and efficacy of CP-690,550 for maintenance therapy in subjects with moderate to severe Crohn's disease.	IIb	Globaly 275, India 75	<ol style="list-style-type: none"> <li>1. Dr. Abraham Koshy, Lakeshore Hospital &amp; Research Center Ltd. NH-47 Bypass, Maradu, Nettoor P.O., Kochi – 682040.</li> <li>2. Dr. Amol Bapaye, Deenanath Mangeshkar Hospital &amp; Research Center, Department of Digestive Diseases &amp; Endoscopy, 11 Floor, Wing B, Erandwane, Pune-411004, India.</li> <li>3. Dr. Rupa Banerjee, Asian Institute of Gastroenterology, 6-3-661, Somajiguda, Hyderabad, A.P, India.</li> <li>4. Dr. Shine Sadasivan, Amrita Institute of Medical Sciences And Research Center, Amrita Lane, Ponekkara P.O.-Edappally,Kochi-41.</li> <li>5. Dr Vinay Thorat, Poona Hospital &amp; Research Centre, 27, Sadashiv Peth, Pune 411030.</li> <li>6. Dr. Philip Abraham, P.D. Hinduja National Hospital &amp; Medical Research Centre Veer Savarkar Marg, Mahim, Mumbai, Maharashtra 400 016.</li> </ol>	1/11/2012
---	----------	------------	----------	--------	---	-----	-----------------------	---	-----------

7	CT/54/12	Bocepravir	MK-3034 or SCH503034	MSD	A Phase 3, safety and efficacy study of boceprevir/peginterferon alfa 2a/ribavirin in chronic HCV genotype 1 IL28B CC subjects.	III	Globally 1250 India 80	<ol style="list-style-type: none"> <li>1. Dr. Deepak Amrapurkar, Bombay Hospital &amp; Medical Research Centre, Bombay Hospital, 12, Marine Lines, Mumbai 400020.</li> <li>2. Dr. Ajit Sood , Dayanand Medical College &amp; Hospital, Department of Gastroenterology, Civil Lines, Ludhiana141001.</li> <li>3. Dr. V G Mohan Prasad, V G M Hospital and Institute of Gastroenterology, 2180, Trichy Road, Rajalakshmi Mills Stop, Coimbatore 641005.</li> <li>4. Dr. Kaushal Vyas, Gujarat Gastro Group 201, Silver Brook A, Opp. Doctor house, Parimal Garden, Ellisbridge, Ahmedabad .</li> <li>5. Dr. Nitin Pai , Pai Clinic and Diagnostic Center, 778/B-1, Abhinav apartments, Next to congress house, Shivaji nagar, Pune 411005 .</li> <li>6. Dr. Samir Shah, Diwaliben Mohanlal Mehta Charitable Trust, Khatau Mansion, 95/K Bhulabhai Desai Road, Mumbai-400036</li> <li>7. Dr. B. Ravishankar, Yashoda Hospital, Alexander Road, Kummari Guda, Secunderabad-500003.</li> <li>8. Dr. Dharmesh Kapoor, Global Hospitals, 6-1-1040, Lakdi-ka-pul, Hyderabad 500004.</li> <li>9. Dr Rajiv Mehta, Liver Clinic, 203-204, Narmada Complex, 2nd floor, Near Kadiwala school, Ring road, Gujarat.</li> <li>10. Dr. Sandeep Kumar Gupta, M. V. Hospital and Research Centre, Lucknow-226003.</li> <li>11. Dr. Boddhu Prabhakar, Osmania General Hospital, Department of Gastroenterology, Liver Care unit, Afzal Gunj, Hyderabad-500012.</li> <li>12. Dr. Murlikrishnan, Manikkya Institute of Gastroenterology, MVV Chambers, Near KGH OP Gate Bus Stop, Maharani Peta, Vishakhapatnam-530002.</li> <li>13. Dr. K. T. Shenoy, Sree Gokulam Medical College, Karinchathi Road, Venjaramoodu, Trivandrum-695607.</li> <li>14. Dr. Varadaraj Gokuk, Asian Institute of Gastroenterology, 6-3-661, Somajiguda, Hyderabad-500082.</li> <li>15. Dr. Joy Verghese, Global Hospitals &amp; Health 201,</li> </ol>	1/11/2012
---	----------	------------	----------------------	-----	---	-----	------------------------------	--	-----------

8	CT/68/12	Mometasone Furoate	CQMF149E22 01	Novartis	A randomized, double blind, double dummy, 4week treatment, parallel group study to evaluate the efficacy and safety of two doses of mometasone furoate delivered via Concept1 or Twisthaler in adult and adolescent patients with persistent asthma	II	Globally 616 India 100	<ol style="list-style-type: none"> <li>1. Dr. Ajay Navinchandra Shah, Gujarat Pulmonary &amp; Critical Care Clinic, Ahmedabad-380009.</li> <li>2. Dr. B. V. Murali Mohan, Narayana Hrudayalaya Hospitals, Bangalore-560099.</li> <li>3. Dr. Hirennappa. B. Udnur, Pace Clinical Research Center, Bangalore-560043.</li> <li>4. Dr. Devasahayam Jesudas Christopher, Department of Pulmonary Medicine, Christian Medical College Vellore-632004, TamilNadu.</li> <li>5. Dr. Srikanth Krishnamurthy, PSG Hospitals, Coimbatore-641004, Tamil Nadu.</li> <li>6. Dr. Mahesh Chandra Goyal, Jaipur Allergy &amp; Asthma Centre, Jaipur-302001, Rajasthan.</li> <li>7. Dr. Kontur Narayana Mohan Rao, MS Ramaiah Medical College and Hospitals, Bangalore-560054; &amp; MS Ramaiah Clinical Research Hospitals Center, Bangalore-560054, Karnataka.</li> <li>8. Dr. Anil Kumar, Department of Pulmonary &amp; Critical Care Medicine, Dayanand Medical College &amp; Hospital, Ludhiana-141 001, Punjab.</li> <li>9. Dr. Judo Joseph Vachaparambil, West Fort Hi-Tech Hospital Ltd., Thrissur - 680 002, Kerala.</li> <li>10. Dr. Sundeep Santosh Salvi, Chest Research Foundation Mariglod Premises, Pune-411014.</li> <li>11. Dr. Rajiv Premilal Paliwal, Shree Krishna Hospitals and Medical Research Centre, Karamsad-388325, Gujarat.</li> <li>12. Dr. Srinivasan Nagarajan, Coimbatore Chest Clinic, Coimbatore-641002, Tamil Nadu.</li> <li>13. Dr. Rajesh Venkitakrishnan, Amrita Institute of Medical Sciences, Kochi-682 041, Kerala.</li> <li>14. Dr. Akash Lataru Balki, Shree Hospital &amp; Critical Care Centre, Nagpur-440009, Maharashtra.</li> <li>15. Dr. Vipul Khandelwal, Apex Hospitals Private Limited, Jaipur -302 017, Rajasthan.</li> <li>16. Dr. Sathish K. S. Chest and Maternity Centre, Bangalore-560 010, Karnataka.</li> </ol>	24-12-12
---	----------	--------------------	---------------	----------	---	----	------------------------------	--	----------

9	CT/43/12	NVC-422	CL1104	Quintiles	A multicenter, randomized study of the efficacy and safety of NVC-422 ophthalmic solution for the treatment of adenoviral conjunctivitis	II	Globally 440 India 200	<ol style="list-style-type: none"> <li>1. Dr. P. S. Girija Devi, Regional Institute of Ophthalmology, Trivandrum.</li> <li>2. Dr. K. Namitha Bhuvaneswarari, Regional Institute of Ophthalmology, Government Ophthalmology Hospital, Chennai.</li> <li>3. Dr. Usha Vyas, Shri C. H. Nagri Municipal Eye Hospital, Ahmedabad-380006.</li> <li>4. Dr. Manisha Acharya, Dr. Shroffs Charity Eye Hospital, Daryaganj-110002 New Delhi.</li> <li>5. Dr. Prashant Garg, L. V. Prasad Eye Hospital, Hyderabad-500 034, Andhra Pradesh.</li> <li>6. Dr. Chandrashekhar Wavikar, Wavikar Eye Institute, Thane-400601, Maharashtra.</li> <li>7. Dr. Yasmin Bhagat, St. Georges Hospital Fort, Mumbai-400001.</li> <li>8. Dr. Pankaj Gupta, Post Graduate Institute of Medical Education &amp; Research, Chandigarh.</li> <li>9. Dr. P. N. Biswas, Regional Institute of Ophthalmology. Kolkatta-700073, West Bengal.</li> <li>10. Dr. Anjali Nicholson, T. N. Medical College &amp; B. Y. L. Nair Hospital, Mumbai.</li> <li>11. Dr. Vupputuri Venkata Lakshmi Narasimha Rao, Government Regional Eye Hospital, Vishakhapatnam.</li> <li>12. Dr. Shree Kumar Reddy, Apollo Health City, Apollo Hospitals Jubilee Hills, Hyderabad-500 096.</li> <li>13. Dr. Malavika Krishnaswamy, M. S. Ramaiah Medical College &amp; Hospitals, Bangalore-560 054.</li> <li>14. Dr. Priti Kapadia, New Civil Hospital, Surat.</li> <li>15. Dr. Shobha, Kini Vasani Eye Care Hospitals, Salem-636004, Tamil Nadu.</li> <li>16. Dr. Anju Kochar, S. P. Medical College &amp; AG Hospital, Dr. B. K Jain Head Research Cell, Bikaner.</li> <li>17. Dr. Nita Shanbag, Omkar Eye Care Center, Mumbai - 80.</li> <li>18. Dr. Nivedita N. Patil, Bay View Clinic, Mumbai-400 004</li> </ol>	14-11-12
---	----------	---------	--------	-----------	--	----	------------------------------	--	----------

10	CT/119/12	QVA149	CQVA149A23 39	Novartis	A placebo and active controlled study to assess the long term safety of once daily QVA149 for 52 weeks in chronic obstructive pulmonary disease (COPD) patients with moderate to severe airflow limitation	III	India-222, Globally- 1224	<ol style="list-style-type: none"> <li>1. Dr. D. J. Christopher, Department of Pulmonary Medicine, Christian Medical College, Vellore-632 004.</li> <li>2. Dr. Anthony Mesquita, TB &amp; Chest Hospital, Goa Medical College, Goa 303002.</li> <li>3. Dr. Srikanth Krishnamurthy, Sri Bala Medical Centre &amp; Hospital, Coimbatore-641 045.</li> <li>4. Dr. Mathew Thomas, Health and Research Centre, Trivandrum-695011.</li> <li>5. Dr. Mohammed Samiuddin, Global Hospitals, Hyderabad-500 004.</li> <li>6. Dr. Ravindra Sarnik, Leela More's Chest Clinic, Nagpur-440012.</li> <li>7. Dr. Sandeep Saboo, Saboo Hospital &amp; Research Centre, Hyderabad- 500 001.</li> </ol>	4/12/2012
11	CT/06/12	Budesonide/Formoterol pMDI	D5896C0002 7	Astra zeneca	A 26 week, randomized, double blind, parallel group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma related events during treatment with Symbicort, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting $\beta_2$ -agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent ( $\geq 12$ years of age) patients with asthma.	III/IV	Globally 11700 India 950	<ol style="list-style-type: none"> <li>1. Dr. Mahesh P.A., Asthma and Chest center, Mysore, Karnataka.</li> <li>2. Dr. Krishnamurthy Srikant, PSG Hospital, Coimbatore, Tamil Nadu</li> <li>3. Dr. a. Mesquita, T.B. and Chest Hospital, Caranzelem, Goa</li> <li>4. Dr. s. Nagarajan, Coimbatore Chest Clinic, Coimbatore</li> <li>5. Dr. Ravindra Sarnaik, Leela More Chest Clinic, Nagpur, Maharashtra</li> <li>6. Dr. Rajesh Swarnakar, Getwellhospital and Research Institute, Nagpur</li> <li>7. Dr. Pradhyut Waghay, Trirup Medical and Research Foundation, Hyderabad</li> <li>8. Dr. Rajendra Mehta, Dr. Mehta's Allergy's and asthma care and Research Center, Indore, Madhya Pradesh</li> <li>9. Dr. Satish, chest and maternity Centre, Bangalore</li> <li>10. Dr. Binu Krishnan, P.R.S. Hospital, Trivandrum</li> <li>11. Dr. Hansraj Alva, Vinaya Hospital and Research Center, Mangalore</li> <li>12. Dr. Vijil Rahulan, Global Hospital and Health City, Chennai</li> <li>13. Dr. J, C. Suri, safdarjung Hospital, New Delhi</li> <li>14. Dr. Animesh Arya, Centre for Chest Diseases, New Delhi</li> <li>15. Dr. ravindran C., Calcutta Medical College, Calicut</li> </ol>	1/8/2012

12	CT/131/11	Palifosfamide-tris	IPM3001	PPD	A Phase III multicenter, international, randomized, double blind, placebo controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus placebo in patients with front line metastatic soft tissue sarcoma	III	Globally 424 India 20	<ol style="list-style-type: none"> <li>1. Dr. Anish Maru, SEAROC Cancer Center, Jaipur</li> <li>2. Dr. Anjna Surath, Krishna institute of medical sciences, Secunderabad</li> <li>3. Dr. rajnish Vasant nagarkar, curie manavata cancer Centre, nashik, maharashtra</li> <li>4. Dr. Almel Sachin Vamanrao, P.d. Hinduja national Hospital and medical resaerch center, Mumbai</li> <li>5. Dr. Sachin Hingmire, Deenanath Mangeshkar Hospital and Research Center, Pune</li> <li>6. Dr. Shona Nag, Jehangir hospital, Pune</li> <li>7. Dr. Sreejith Gopinathan nair, Regional Cancer Centre, trivandrum</li> </ol>	30-01-12
13	CT/10/12	Buspiron	LB1005	Accutest	Pahse III, prospective, open label, parallel, multicenter, randomized clinical trial for comparative evaluation of efficacy and safety of buspirone (ansitec) and sertraline in the treatment of Generalized Anxiety Disorder (GAD)	III	India 114	<ol style="list-style-type: none"> <li>1. Dr. Nehal Shah, Vraj Hospital, Ahmedabad</li> <li>2. Dr. Bhavesh Lakdawala, B. J. Medical college and Civil Hospital, Ahmedabad</li> <li>3. Dr. Vaishal Vora, Sneh Clinic, Ahmedabad</li> </ol>	9/5/2012

14	CT/05/12	Saxagliptin	CV181147	BMS	A multicenter, randomized, doubleblind, placebo controlled study to evaluate the efficacy and safety of saxgliptin (BMS-477118) in combination with metformin IR or metformin XR in pediatric patients with type 2 Diabetes who have inadequate glycemic control on metformin alone.	III	India- 23 Globally-236	<ol style="list-style-type: none"> <li>1. Dr. Sarika Prasad, Aadithya Adhikari Hospital, Mysore</li> <li>2. Dr. kandregula appala Venkata subrahmanyam, King george hospital, Vishakhapatnam</li> <li>3. Dr. mala Dharmalingam, bangalore Endocrinology and Diabetes resaerch center pvt. Ltd., bangalore</li> <li>4. Dr. Siddaiah rangathiah, Mysore Clinisearch, Mysore</li> <li>5. dr. kandregula dileep Kumar, Vishaka Diabetes and endocrine Center, Vishakhapatnam</li> <li>6.dr. pramila Kalra, M.s. ramaiah Medical college and hospitals, bangalore</li> <li>7. Dr. manoj chadha, P.d. Hinduja national Hospital and Medical Resaerch Centre, Mumbai.</li> <li>8. Dr. kandikattu Uma mahesh, M.v. Hospital for Diabetes Pvt. Ltd</li> <li>9. Dr. babruwad ramesh ganapati, hubli Clinical resaerch centre, karnataka</li> </ol>	23-07-12
15	CT/224/11	R04917838	NN23310	Quintiles	A Phase III, multicenter, randomized, 24 week, double blind, parallel group, placebo controlled study to evaluate efficacy and safety of R04917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double blind treatment period	III	India- 90 Globally-630	<ol style="list-style-type: none"> <li>1. Dr. Satheesh Rao, Centre for Psychiatric Research, Mangalore</li> <li>2. Dr. Supriya Hegde, Kasturba Medical College Hospital, Mangalore</li> <li>3. Dr. Dattatreya Madhav Dhavale, Poona Hospital and research Centre, Pune</li> <li>4. Dr. Sandip Shah Hasmukhlal, Brij psychiatry Hospital and muskaan resaerch center, Vadodara</li> <li>5. Dr. Vaishal Nareshchandra Vora, Sneh Clinic, ahmedabad</li> <li>6. Dr. Mrugesh Dharnidharprasad Vaishnav, samvedna Psychiatry and Sex therapy Hospital, Ahmedabad</li> <li>7. Dr. Anil Kumar Tambi, Mental Health care and Research, jaipur</li> <li>8. Dr. Manoj Kumar Sahu, Pt. JNM Medical college and Dr. B. R. Ambedkar Hospital, Chhatisgarh</li> <li>9. Dr. rakesh Yadav, r.K. Yadav Memorial Mental Health and De-addiction Hospital, Jaipur</li> <li>10 Dr. Pradip Bhikhalal Vaghasiya, Gujarat Institute of Psychological Sciences and research Centre</li> <li>11. Dr. Sundeep Dattatraya Jadhav, Manav Neuropsychiatric Hospitals Pvt. Ltd, kalyan, Mumbai</li> </ol>	12/7/2012

16	CT/224/11	PF-04937319	B1631007	Pfizer	A phase 2, randomized, double blinded, placebo controlled, dose-ranging parallel group study to evaluate safety and efficacy of PF-04937319 and sitagliptin on glyceemic control in adult patients with type 2 diabetes mellitus inadequately controlled on metformin	II	Globally 300 India 100	<ol style="list-style-type: none"> <li>1. Dr. Sunil Jain, Total Diabetes Hormone Institute, indore</li> <li>2. Dr. sanjay A.C. Reddy, Medisys Clinisearch India Pvt. Ltd.,</li> <li>3. Dr. Hemant Thacker, Bhatia Hospital Hospital, Mumbai,</li> <li>4. Dr. Jugal Bihari Gupta, S. R, jaipur. Kalla Memorial Gastro and General Hospital</li> <li>5. Dr. Pramod Gandhi, Gandhi's Resarch Institute, nagpur</li> <li>6. Dr. Nalini Samir Shah, Seth G S Medical college and KEM Hospital, Mumbai</li> <li>7. Dr. Mohan Magdum, Jehangir Hospital, Pune</li> <li>8. Dr. Harish Kumar, Amrita Institute of Medical Sciences and Research Centre, Amrita Lane</li> </ol>	11/7/2012
----	-----------	-------------	----------	--------	---	----	---------------------------	---	-----------

17	CT/40/12	CP-690,550	A3921139	Pfizer	A multicenter, open label study of CP-690550 in subjects with moderate to severe ulcerative colitis	III	Globally 725, India 135	<ol style="list-style-type: none"> <li>1. Dr. Abhijit Chandra, Chhatrapati Shahuji Maharaj Medical University, Lucknow.</li> <li>2. Dr. Bhabadev Goswami, Institute of Digestive &amp; liver disease, Ganeshguri, Guwahati.</li> <li>3. Dr. Mayank Kabrawala, Gastro Intestinal Endoscopy Center, Sagrampura, Kailashnagar, Surat, Gujarat.</li> <li>4. Dr. Mukesh Kalla, S.R.Kalla Memorial Gastro &amp; General Hospital, Sardar Patel Marg, Jaipur.</li> <li>5. Dr. Shrikant Mukewar, Midas Multispeciality Hospital, Midas Heights, Central Bazar Road, Nagpur.</li> <li>6. Dr. Vinay Thorat, Poona Hospital &amp; Research Center, Sadashiv Peth, Pune.</li> <li>7. Dr. Abraham Koshy, Lakeshore Hospital &amp; Research Center Ltd., Maradu, Kochi, Kerala.</li> <li>8. Dr. Chetan Mehta, Gastrocare Clinic, Karansinhji Main Road, Rajkot.</li> <li>9. Dr. Rupesh Mehta, Mehta Hospital, 57, Brahmin Mitra Mandal Society, Paldi, Ahmedabad.</li> <li>10. Dr. Murali Krishna Palakurthy, Manikya Institute of Gastroenterology &amp; Hepatology, MVV Chambers, Maharanipeta, Visakhapatnam.</li> <li>11. Dr. Boddu Prabhakar, Osmania General Hospital, Afzalgunj, Hyderabad.</li> <li>12. Dr. V. G. Mohan Prasad, VGM Hospital, Institute of Gastroenterology, Trichy Road, Coimbatore.</li> <li>13. Dr. Vishwanath B Tantry, Manipal Center For Clinical Research, Kasturba Medical College Hospital, Mangalore, Karnataka.</li> <li>14. Dr. Hasmukh Vora, Sushrusha Hospital, Navrangpura, Ahmedabad.</li> </ol>	19-10-12
----	----------	------------	----------	--------	---	-----	-------------------------	--	----------

18	CT/42/12	Vandetanib	D4200C0009 7	Quintiles	An international, randomised, double-blind, two-arm study to evaluate the safety and efficacy of Vandetanib 150 and 300mg/day in patients with unresectable locally advanced or metastatic medullary thyroid carcinoma with progressive or symptomatic disease	IIIb/IV	Globally 80 India 12	1. Dr. Bharath Rangarajan, narayana Hrudalaya Hospitals, Bangalore 2. Dr. Kumar Prabhash, Tata Memorial Hospital, Mumbai 3. Dr. Suresh Attili, Bibi General hospital and cancer Centre, hyderabad 4. Dr. Rajo Chacko, Christian Medical college, Vellore, Tamil Nadu	10/9/2012
19	CT/197/11	Vemurafenib	MO25515	Roche	An open label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma	IV	Globally 900, India 12	1. Dr. raghunadharao Digumarti, Nizam's institute of Medical sciences, hyderabad 2. Dr. sanjeev misra, King George Medical college, Lucknow 3. Dr. rajnish Nagarkar, curie manvata cancer Centre, nashik, Maharashtra 4. Dr. ullas batra, rajiv gandhi cancer Institute and Research centre, New Delhi	18-04-12
20	CT/74/11	Niacin/Laropiprant	MK-0524A-133	Covance	A worldwide, multicenter, double-blind, randomized, parallel, placebo controlled 12 week study to evaluate the efficacy and safety of extended release niacin/laropiprant when added to ongoing lipid modifying therapy in patients with primary hypercholesterolemia or mixed dyslipidemia	III	India -27, Globally-1424	1. Dr. Ravi Kisore, Narayana Hrudalaya Hospitals, Bangalore 2. Dr. Shailesh Pitale, Pitale Diabetes and Hormone Center, Nagpur 3. Dr. Subhash Kumar Wangnoo, Indraprastha Apollo Hospital, New Delhi	14-06-12

21	CT/108/11	Oxycodone-Naloxone		Kendle	<p>A randomised, double blind, double dummy parallel group, multicenter study to demonstrate improvement in symptoms of constipation and non-inferiority in analgesic efficacy in subjects in subjects with non-malignant or malignant pain that requires around the clock opioid therapy taking 50/25-80/40mg twice daily as oxycodone/naloxone prolonged release (OXN PR) tablets compared to subjects taking 50-80mg twice daily oxycodone prolonged release (OxyPr) tablets alone</p>	III	Globally-270 India - 54	<p>1. Dr. satheesh Chiradoni Thungappa, Sri Venkateshwara Hospital, Bangalore  2. Dr. Shashank Tiwari, M.V. Hospital and Research center, Lucknow  3. Dr. Bharat Modi, Centre for Knee and hip Surgery, Baroda, gujarat  4. Dr. Gaurav J. Rathi, Rathi Orthopedic and Research centre, Ahmedabad  5. Dr. Ravindrasingh Raj, Bharat cancer Hospital and Resaerch Institute, Surat  6. Dr. Rajiv Rai Choudhury, Advanced Surat Traumatology and Orthopedic Surgery Hospital, Surat, Gujarat  7. Dr. Pradeep jain, Sir Ganga Ram Hospital, New Delhi  8. Dr. Pushplata Gupta, Bhagwan Mahaveer Cancer Hospital and resaerch centre, jaipur  9. Dr. N K Vinod, rangadore Memorial Hospital, Bangalore  10. Dr. Vinay Bhomia, Sanjivani super specilaity Hospital, ahmedabad  11. Dr. Mohd. Athar, rajaji Puram Hospital and Maternity Centre, Lucknow  12. dr. anil Kumar awasthi, ajanta Hospital, Lucknow</p>	3/4/2012
----	-----------	--------------------	--	--------	---	-----	----------------------------	---	----------

22	CT/113/11	Fluticasone Propionate	FLT3506	Kendle	A double blind, double dummy, randomized, parallel group multicentre study to compare the efficacy and safety of Flutiform pressurized metered dose inhaler with Fluticasone pressurized metered dose inhaler and with seretide pressurized metered dose inhaler in paediatric subjects aged 5 to less than 12 years with severe persistent reversible asthma	III	<ol style="list-style-type: none"> <li>1. Dr. Akash Balki, shree Hospital and Critical Care Center, nagpur</li> <li>2. Dr. Krishnan Chugh, sir Gangaram Hospital, New Delhi</li> <li>3 Dr. Manish Jain, Shwaas Center, Navkar Hospital, Jaipur</li> <li>4. Dr. tushar patel, Sterling Hospital, ahmedabad</li> <li>5. Dr. mathew Thomas, Health and research center, Trivandrum</li> </ol>	2/5/2012
----	-----------	------------------------	---------	--------	---	-----	--	----------

23	CT/116/11	OPC-34712	331-10-237	Quintiles	A long term, phase III, multicentre, open label trial to evaluate the safety and tolerability of oral OPC-34712 as maintenance treatment in adult with schizophrenia	III	Globally 1000 India 160	<ol style="list-style-type: none"> <li>1. DR. Sabyasachi Mitra, B.P. Poddar Hospital and Medical Research Ltd., Kolkata</li> <li>2. Dr. Hitendra Amritlal Ghandi, sheth Vadilal sarabhai Hospital and Municipal Medical College, Ahmedabad</li> <li>3. Dr. Vishlal India, Vijaywada Institute of Mental Health and Neurosciences, Vijayawada, andhra Pradesh</li> <li>4. Dr. Vinay Laxmikantrao Barhale, shanti Nursing home, aurangabad</li> <li>5. Dr. Ramesh Kumar mahendru, mahendra Psychiatric centre, Kanpur</li> <li>6. Dr. ramanathan sathianathan. Madras medical College and Govt. General Hospital, Chennai</li> <li>7. Dr. B. S.V. Prasad, Sujata Birla Hospital and Medical Resaerch Centre, nashik</li> <li>8. Dr. Rakesh Yadav, R.K.Yadav Memorial Mental Health and De-addiction Hospital, jaipur</li> <li>9. Dr. T. S. sathanarayananana rao, JSS Medical College and Hospital, ramanuja road, Mysore</li> <li>10. Dr. D. M. Dhavale, Poona Hospital and research Center, Pune</li> <li>11. Dr. Ravish Thunga, Thunga Institute of Psychiatry and Counselling, Mangalore</li> <li>12. Dr. Venu Gopal Jhanwar, eva Mental Health care, varanasi</li> <li>13. Dr. ramasubramaniam Chellamuthu, radianz Clinical resaerch, tamil nadu</li> <li>14. Dr. sanjay Phadke, deenanath Mangeshkar Hiospital and resaerch center, Pune</li> <li>15. Dr. mahesh chudgar, Mental illness Treatment Rehabilitation Foundation</li> <li>16. Dr. sandip Hashmukhlal Shah, Brij Psychiatric Hospital</li> <li>17. Dr. Pradip Vaghasiya, gujarat Institute of Psychological Research, ahmedabad</li> </ol>	7/3/2012
----	-----------	-----------	------------	-----------	--	-----	----------------------------------	--	----------

24	CT/215/11	NAV237 inhalation capsule	CNVA237A2309	Novartis	a 26 week treatment, randomized, double-blind, placebo-controlled parallel group study to assess the efficacy, safety and tolerability of NVA237 (50µg o.d.) in patients with chronic obstructive pulmonary disease	III	Globally 450 India 80	1. Dr. Rajendra Mehta, Dr. Mehta's Allergy and Asthma care and research Centre, Indore 2. Dr. Animesh Arya, Center for Chest Diseases, New Delhi	30-07-12
25	CT/161/11	AZD4547	D3820C00013	Astra zeneca	A randomised, open label phase II study to assess the efficacy and safety of AZD4547 monotherapy versus paclitaxel in patients with advanced gastric adenocarcinoma (including adenocarcinoma of the lower third of the oesophagus or the gastro-oesophageal junction) with FGFR2 polysomy or gene amplification	II	Globally 55 India 12	1. Dr. Chetan Deshmukh, Deenanath Mangeshkar Hospital and research Centre, Pune 2. Dr. radheshyam naik, HCG bangalore institute of Oncology, bangalore 3. Dr. Suresh Attili, BIBI General hospital and cancer Centre, Hyderabad 4. Dr. Suresh Attili, BIBI General hospital and cancer Centre, Hyderabad 5. Dr. raju Titus Chacko, Christian Medical college, Vellore 6. Dr. Shona nag, Jehangir hospital, Pune	30-01-12

26	CT/13/11	CF101	CF101-231GL	Karmic	A Phase 2, multicenter, randomised, double blind, placebo controlled, parallel group study of the efficacy and safety of daily CF101 administered orally as monotherapy for 12 weeks in patients with active rheumatoid arthritis and elevated baseline expression levels of peripheral blood mononuclear cell A3 adenosine receptors	II	Globally 80 India 70	1. Dr. Firdaus Fatima, olive hospital, Hyderabad 2. Dr. Hemant s. Magar, Giriraj hospital, Pune 3. Dr. Jagtap Nilesh Ramrao, Royal hospital, Pune 4. Dr. Jyotsna Oak, Kokilaben Dhirubhai Ambanihospital, Mumbai 5. Dr. Rajkumar Jagdish Mukhi, Memorial medical center, Mumbai 6. Dr. Sushrut S. Babhulkar, Sushrut Hospital, Nagpur 7. Dr. Vivek v. Jabade, Jabade hospital, Pune	24-04-12
27	CT/152/11	Aripiprazole	31-10-274	Covance	An open label, multicenter study evaluating the safety and tolerability of once weekly oral aripiprazole in children and adolescents with Tourette's Disorder	III	Globally 192 India 25	1. Dr. Venu Gopal Jhanwar, Deva Mental Health care, Varanasi 2. Dr. V. Rajesh P. Udani, P.D. Hinduja National Hospital and Medical Research Centre, Mumbai 3. Dr. Mahendru Ramesh Kumar, Mahendru Psychiatric Centre, Kanpur 4. Dr. T. S. Sathyanarayanan Rao, J.S.S. Medical College and Hospital, Mysore 5. Dr. Shankara Nellikunja, Mallikatta Neuro Centre, Mangalore	2/5/2012

28	CT/23/12	PF-04937319	A3921084	Pfizer	A phase 2, randomized, double blinded, placebo controlled, dose-ranging parallel group study to evaluate safety and efficacy of PF-04937319 and glimepiride in adult patients with type 2 diabetes mellitus inadequately controlled on metformin	II	Globally 300, India 75	<ol style="list-style-type: none"> <li>1. Dr. Chittaranjan Yajnik, KEM Hospital Resaerch center, Pune</li> <li>2. Dr. Hemraj Chandalia, Diabetes Endocrine Nutrition management and Research Centre, Mumbai</li> <li>3. Dr. vaishali Deshmukh, deenanath mangeskar hospital and research Centre, Pune</li> <li>4. Dr. anuradha Muddana, Diabetomics India Pvt. Ltd, Diabetomics India Pvt. Ltd, Hyderabad</li> <li>5. Dr. Vyankatesh Shivane, Researcg Health Institute in Diabetes Endocrinology and Metabolism, Mumbai</li> <li>6. Dr. ramanathan Balamurugan, Kovai Diabetes Speciality centre, coimbatore</li> <li>7. Dr. Neeta Deshpande, Belgaum Diabetes Centre, Belgaon, karnataka</li> <li>8. Dr. satish Babu, BGS Global hospital, Bangalore</li> <li>9. Dr. Sunil Gupta, diabetes care and Research Centre, nagpur</li> <li>10 Dr. surendra sharma, diabetes and Tyroid and Endocrine Centre, jaipur</li> <li>11. Dr. satyanarayana srikanta, jnana Sanjeevani Medical Centre, Bangalore</li> </ol>	14-06-12
29	CT/209/11	Lopinavir/Ritonavir+Raltegravir	A5273	YRG Care, NARI, BJ Medical College	A Phase III, dual arm, open label, randomized, non - inferiority study for participants who are on a failing non-nucleoside reverse transcriptase inhibitor (NNRTI) containing first line regimen.	III	Total 600	<ol style="list-style-type: none"> <li>1. Dr. Nagalingeswaran Kumarasamy, YRG care, Chennai</li> <li>2. Dr. Raman Gangakhedkar, National aids Research Institute, Pune</li> <li>3. Dr. Dileep Kadam, B.J. Medical college and sassoon General Hospital, Pune</li> </ol>	2/5/2012

30	CT/193/11	Linagliptin	1218.3	Boehringer	A 24 week, randomized, double blind, randomized, double-blind, active controlled, parallel group trial to assess the superiority of oral linagliptin and metformin compared to linagliptin monotherapy in newly diagnosed, treatment naive, uncontrolled Type 2 Diabetes Mellitus patients.	IV	India- 50 Globally-270	<ol style="list-style-type: none"> <li>1. Dr. Vijay Vishwanathan, M.V. Hospital for Diabetes, chennai</li> <li>2. Dr. Shivane Vyankatesh Krishnacharya, Research Health Institute in Diabetes Endocrinology and metabolism, Mumbai</li> <li>3. Dr. s. parmash, bangalore Clinisearch, Bangalore, karnataka</li> <li>4. Dr. mala Dharmalingam, bangalore endocrinology Diabetes and resaerch center, bangalore</li> <li>5. Dr. Shaikh Shehla Sajid Akhtar, KGN Diabetes and Endocrinology Centre, Mumbai.</li> </ol>	31-07-12
----	-----------	-------------	--------	------------	---	----	---------------------------	---	----------

31	CT/179/11	Cariprazine	RGH-MD-06	Quintiles	A randomised, double blind, placebo controlled, parallel group study of cariprazine (RGH-188) in the prevention of relapse in patients with schizophrenia	III	Globally 900 India 270	<ol style="list-style-type: none"> <li>1. Dr. Jitendra Kumar trivedi, Manobal Medical research Center Pvt. Ltd, Lucknow, UP</li> <li>2. Dr. R C maniar, Gujarat Institute of Psychological Sciences and Research Center, Ahmedabad, Gujarat</li> <li>3. Dr. Rohan Kusumgar, Ashray Hospital, ahmedabad, Gujarat</li> <li>4. Dr. C. Subramaniam, radianz Clinical research Unit, Madurai, tamil Nadu</li> <li>5. Dr. Bandana Gupta, Chhatrapati Shahuji Maharaj Medical University, Lucknow, UP</li> <li>6. Dr. arti Behl Apollo BGS Hospital, Mysore, Karnataka</li> <li>7. Dr. mahesh Chudgar, Mental Illness Treatment and Rehabilitation Foundation, ahmedabad</li> <li>8. Dr. Hitendra gandhi, Sheth Vadilal sarabhai General hospital and Municipal Medical college, ahmedabad</li> <li>9. Dr. Vishal Indla, Vijaywada Institute of Mental Health and Neuro sciences, Vijayawada</li> <li>10. Dr. Sathhesh rao, Centre for Psychiatric Research, Mangalore</li> <li>11. Dr. Venugopal Jhanwar, deva Mental Health care, varanasi</li> <li>12. Dr. Vinay Barhale, Shanti Nursing Home, aurangabad</li> <li>13. Dr. sundeep Jadhav, Manav Neuro Psychiatric Hospitals Pvt. Ltd, Mumbai</li> <li>14. Dr.B.S.V. Prasad, Sujata Birla Hospital and Medical reserach center, nashik road, maharashtra</li> <li>15. Dr. Vishal Sonawane, Chaitanya Mental Health Care Centre, Pune</li> <li>16. Dr. Manas Sule, Dr. Kulkarni Nursing Home, nashik, Maharashtra</li> <li>17. Dr. Manish Bhargava, Bhagwan Mahaveer Psychiatric and de-addiction center, Jaipur</li> <li>18. Dr. ramesh Kumar Mahendru, mahendru Psychiatric Center, Kanpur, Uttar Pradesh</li> </ol>	7.03.2012
----	-----------	-------------	-----------	-----------	---	-----	------------------------------	---	-----------

32	CT/168/11	Tiotropium + Olodaterol	1237.6	Boehringer	<p>A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium+olodaterol fixed dose combination (2.5 µg/and 5 µg; 5 µg ) delivered by the Respimate<sup>®</sup> Inhaler) compared with the individual component (2.5 µg/and 5 µg Tiotropium, 5µg olodaterol) (delivered by the Respimat<sup>®</sup> Inhaler in patients with Chronic Obstructive Pulmonary Disaese (COPD) (TONado™1)</p>	III	Globally 2500 India 140	<p>1. Dr. Anthony M. Mesquita, MD TB and Chest Hospital, St. Inez, P.O. Caranzalem, Panaji, Goa: 403002  2. Dr. Alope Gopal Ghoshal National Allergy Asthma Bronchitis Institute 11/3, Dr. Birsh Guha Street Kolkata-700017, Ph-033 2290 2305/9830330404  3. Dr. S. Balamurugan Consultant Pulmonologist 2, First Cross, Janaki Nagar Extension, Valasaravakkam, Chennai-600087  4. Dr. Manish Kumar Jain Consulatan Chest Physician Shwaas Centre, Navkar Hospital, G-11, Shubham Apartment, Central Spine, Vidhyaharnagar, Jaipur-302023  5. Dr. Subhasish Ghosh, Consultant Pulmonologist P-4&amp;5, C.I.T. Scheme-LXXII, Block-A Gariahat Road (Beside Dhakuria Bridge), Dhakuria, Kolkata-700029 West Bengal, India  6. Dr. Sujeet K. Rajan Consultant Respiratory Physician Bhatia Hospital G2 Clinic, Tardeo Road, Mumbai-400007, Maharashtra, India  7. Dr. Swarnakar Rajesh Nathuram Director, Getwell Hospital and Research Institute, 20/1, Dr. Khare Marg, Dhantoli, Nafpur 440012 India  8. Dr. Parag G. Khatavkar, MD (Chest), Chest Physician K.E.M. Hospital Research Centre, Sardar Moodliar Road, Rasta Peth, Pune-411011, Maharashtra-India  9. Dr. B.K.Mutha, Consultant Chest Physician Mutha Hospital, P-67, MIDC Satpur, Behind ITI, Trimbak Road Nashik -422007. Maharashtra India  10. Dr. Tushar Sahasrabudhe Professor and Head, Department of Pulmonary Medicine, Padmashree DR. D.Y.Patil Medical College, Pimpri, Pune-41018.  11. Dr. V.Sivakumar Consultant Pulmonologist &amp; Bronchoscopist, Director, Sudha Lung Care and a Research Centre, NO. 5, SKS Clinic, Ramani Complex, Opposite New Bus Stand, Salem-626004</p>	01.02.2012
----	-----------	-------------------------	--------	------------	---	-----	-------------------------------	--	------------

33	CT/199/11	Esmolol Hydrochloride	Novalead-Galnobax-0210	M/s Siro Clinpharm	An interventional, placebo-controlled, randomized, double-blinded, dose comparison, phase I study to determine the safety and efficacy of a new gel formulation of esmolol hydrochloride (galnobax®) for the treatment of diabetic foot ulcer (DFU).	I	Globally 50 India 30-40	<ol style="list-style-type: none"> <li>1. Arun Bal, S.L. Raheja Hospital, Fortis Associate, Mahim Mumbai</li> <li>2. Kale Shailaja Dilip, Clinical Research Unit Orange Diabetes Speciality Clinic , Bibwewadi Road, Pune</li> <li>3. Ajit Kumar Varma, Amtita Vishwavidyapeetham University, AIMS, Ponekkara P.O. Kochi</li> </ol>	4/3/2012
34	CT/20/12	CP-690,550	A39221083	M/s Pfizer	A randomized, double-blind, placebo-controlled, parallel group, multi-centre study to investigate the safety and efficacy of CP-690,550 for induction therapy in subjects with moderate to severe Crohn's disease	III	Globally 275 India 75	<ol style="list-style-type: none"> <li>1. Dr. Abraham Koshy Director Hepatology Lakeshore Hospital &amp; research centre Ltd. NH-47 Bypass, Maradu, Nettoor P.O. Kochi-682040</li> <li>2. Dr. Amol Bapaye Surgical Gastroenterologist &amp; Endoscopist Deenanath Mangeshkar Hospital&amp;Research Center, Dpt. Of Digestive Diseases &amp; Endoscopy, 1st floor, Wing B, Erandwane, Pune-411004, India</li> <li>3. Dr. rupa Banerjee Consultant Gastroenterologist Asian Institute of Gastroenterology 6-3-661, Somajiguda, Hyderabad, A.P. India</li> <li>4. Dr. Shine Sadasivan Clinical Professor Dept. of Gastroenterology, AIIMS, Kochi-41</li> <li>5. Dr. Vinay Throat Poona hospital and research centre, 27 sadashiv peth, Pune-411030</li> <li>6. Dr. Philip Abraham Consultant Gastroenterologist, P.D. Hinduja National Hospital &amp; Research Center, Veer Savarkar Marg, Mahim, Mumbai-400016</li> </ol>	4/19/2012

35	CT/169/11	Tiotropium + Olodaterol	1237.6	M/s Boehringer	<p>A randomized, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium+olodaterol fixed dose combination (2.5µg / 5 µg; 5 µg / 5 µg) (delivered by the Respimat® Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD) [TONADO™ 1]</p>	III	<p>Globally-2500 India-140</p>	<ol style="list-style-type: none"> <li>1. Dr. Virendra Singh Professor &amp; Head of Allergy and Pulmonary Medicine, Dhanvantri OPD Block SMS Hospital, Jaipur-302004 Rajasthan.</li> <li>2. Dr. K.S.Satish Chest and Maternity Centre No 878, 5th Block, Rajajinagar, Banglore- 560010 Karnataka, India</li> <li>3. Dr. Pradyut Waghray (Pulmonologist) 5-9-41/1/A, New MAL Quarters Lane, Basheerbagh, Hyderabad-500029 Andhra Pradesh, India</li> <li>4. Dr. Pattabhi Raman Vallandramam Ranganathan, Consultant Pulmonologist, Kovai Medical Centre and Hospital, P.B.No. 3209, Avinash Road, Coimbatore-641014 Tamilnadu, India</li> <li>5. Dr. Nandagopal Velayuthaswamy. MD, Consultant Pulmonologist Asthma Allergy Respiratory care, Karthick Poly Clinic, 101/67, Karunanidhi Nagar, Behind Sungam Chinthamani, Ramanathapuram, Trichy Road, Coimbatore-641045 Tamilnadu India</li> <li>6. Dr. SUndeep Director, Chest Research Foundation, Survey No 15, Marigold complex, Behind Gold Adlabs, Kalyaninagar, Pune, Maharashtra-411014</li> <li>7. Dr. George D'Souza Professor and Head of the Dept. of the Chest Medicine PFT labs, 5th floor, St. John's Medical College and Hospitals, Sarjapur road, Johnnagar, Bangalore-560034, Karnataka state, India</li> <li>8. Dr. Sharad Tikkiwal Consultant Chest Physician Asthma Bhawan R-3, Sec-6, Vidhyadhar Nagar, Jaipur</li> <li>9. Dr. Mahesh. Padukudru.Anand Director, Allergy Asthma Associates, 1397, IV Cross, Krishnamurthypuram, Mysore-570004</li> <li>10. Dr. Raj Gautam Bhagat M.D. (Gold medalist) M.C.A.I. Dr. Bhagat's Allergy Asthma clinic and Respiratory Care Centre "Pathik", Dashaporwad Society, CNC Pump Lane, B/H Baldi Bus Stand, Baldi</li> </ol>	01.02.2012
----	-----------	-------------------------	--------	----------------	---	-----	--------------------------------	--	------------

36	CT/193/10	Canagliflozin	PO5897	Inventive International	A 26 week, multicenter, open-label, Flexible dose, long-term safety trial of Asenapine in adolescent subjects with schizophrenia	IIIb	Globally 150 India 45	<ol style="list-style-type: none"> <li>1. Dr. N.N.Raju Government Hospital for Mental Care Chinawaltair Visakhapatnam-530017</li> <li>2. Dr. R. Sathianathan Professor of Psychiatry Ward 120, Dept. of Psychiatry Madras Medical College &amp; Government General Hospital Chennai-600003 Tamil nadu</li> <li>3. Dr. P.C.Shastrri Professor M.D.(PSY), d.P.M. 3/3 Vivina Co-op Hsg. Society, S.V.Road. Opp. Andheri Station ,Andhri(West), Mumbai-400058</li> <li>4. Dr. Anil Kumar Tambi Mental Health Care &amp; Research A-500, Govind Marg, Malviya Nagar, Jaipur-302017</li> <li>5. Dr. Thatikonda Padma Sudhakar, Prof. &amp; Head, Dept. of Psychaitry, S.V.Medical College S.V.R.R.G.General Hospital Tirupati-517507, A.P. India</li> <li>6. Dr. Ranjive Mahajan Prof. &amp; Head Dept. of Psychiatry 3rd floor, Ward No-318 Dayanand Medical College &amp; Hospital Ludhiana-141001.</li> <li>7. Dr. Satheesh Rao, Centre for Psychiatric Research</li> <li>8. Dr. Sanjay Phadke, Deenanath Mangeshakar Hospital &amp; Research Centre, Erandawane, Pune-411004</li> <li>9. Gundugurti Prasad Rao, Asha Hosptial, 298, Road No. 14, Banjara Hills, Hyderabad-500034</li> </ol>	04.01.2012
37	CT/90/12	AR-12286	AR-12286-CS205	Max Neeman	A phase 2b, double-masked, randomized, active-controlled, study assessing the safety and ocular hypertensive efficacy of AR-12286 in patients with low tension glaucoma	IIb	India 120	<ol style="list-style-type: none"> <li>1. Dr. Ramanjit Sihota, Dr. Rajendra Prasad centre for Ophthalmic Sciences , AIIMS, New Delhi</li> <li>2. Dr. Rupali Chopra , Christian Medical college and hospital, Ludhiana, Punjab</li> <li>3. Dr. Nivendita Patil , Conwest and Manjula S Badani Jain Hospital , Mummai</li> <li>4. Dr. Reena M. Chowdhary , ICARE eye Hospital and Research, Noida</li> <li>5. Dr. Subodh Kumar Sinha, Venu Eye Institute and Research Centre, New Delhi</li> </ol>	17.09.2012

38	CT/80/12	Sunitinib	A6181202	Pfizer	A single-Arm open-label international multicenter study of the efficacy and safety of Sunitinib Malate (SU011248, SUTENT <sup>®</sup> ) in Patients with Progressive advanced Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors	IV	Globally 80 India 5	1. Dr. Shailesh Vinayak Shrikhande , Tata Memorial Hospital Department of Digestive Disease & Clinical Nutrition Dr. E Borges Marg, Parel , Mumbai	19.10.2012
----	----------	-----------	----------	--------	---	----	---------------------------	--	------------

39	CT/33/12	CP-690,550	A3921096	Pfizer	A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	III	Globally 654 India 120	<p>1. Dr Abhijit Chandra, Chhatrapati Shahuji Maharaj Medical University Department of surgical Gastroenterology, Chowk, Lucknow, Uttar Pradesh 226003, INDIA</p> <p>2. Dr Bhabadev Goswami, Institute of Digestive and Liver Diseases Dispur Hospitals Ltd, Ganeshguri, Guwahati, Assam 781006, INDIA</p> <p>3. Dr Mayank Kabrawala, Gastro Care - Gastro Intestinal Endoscopy Centre C-150, Shankheshwar Complex, Opp. Raymond Show Room, Kailash Nagar, Sagrampura, Surat, Gujarat 395 002, INDIA</p> <p>4. Dr Mukesh Kalla, S.R. Kalla Memorial Gastro &amp; General Hospital 78, Dhuleshwar Garden, Behind HSBC Bank, Sardar Patel Marg, C-Scheme, Jaipur, Rajasthan 302001, INDIA</p> <p>5. Dr Chetan Mehta, Gastro care Clinic, Opp Dr Bharat Parekh Hospital, Karansinhji Main Road, Rajkot, Gujarat 360001, INDIA</p> <p>6. Dr Shrikant Mukewar, Midas Multispeciality Hospital Pvt., Ltd, 07, Central Bazar Road, Ramdaspath, Nagpur, Maharashtra 440010,</p> <p>7. Dr Vinay Thorat , Poona Hospital and Research Centre, 27, Sadashiv Peth, Pune, 411 030, INDIA</p> <p>8. Dr Abraham Koshy, Lakeshore Hospital and Research Centre, NH 47 Bypass, Maradu, Nettoor P.O Kochi , Kerala 682 040 INDIA</p> <p>9. Dr Rupesh Mehta, Mehta Hospital,57, Brahmin Mitra Mandal Society, B/W Paldi Bus Stop &amp; Jalaram Mandir Paldi, Ahmedabad, Gujarat 380006, INDIA</p> <p>10. Dr. Murali Krishna Palakurthy, Manikya Institute of Gastroenterology and Hepatology M V V Chambers, Near KGH OP Gate Bus stop, Maharani peta, Visakhapatnam, Andhra Pradesh 530002, INDIA</p> <p>11. Dr Boddu Prabhakar, Department of Gastroenterology, Hepatology and</p>	19.10.2012
----	----------	------------	----------	--------	---	-----	------------------------------	---	------------

40	CT/03/12	Stavudine	WRHI001	PPD	A Randomised, Double-Blind, Multi-Centre, Parallel-Group Phase 3b Study to Demonstrate Non-inferiority of Stavudine (20 mg Twice Daily) Compared with Tenofovir Disoproxil Fumarate (300 mg Once Daily) When Administered in Combination With Lamivudine and Efavirenz in Antiretroviral-Naive Patients Infected With HIV-1	III	Globally 1068 India 356	1. Dr. Nagalingeswaran Kumarasamy Chief Medical Officer & Clinical Research YRGCARE Medical Centre VHS, Chennai CRS Yr Gailtonde Medical, Educational & Research Foundation Voluntary Health Services, Rajiv Gandhi Salai, Taramani, Chennai-600113. India	4/24/2012
----	----------	-----------	---------	-----	---	-----	-------------------------------	--	-----------

41	CT/228/11	RP5063	RVR-20-001	Sristek	REFRESH: Randomized, double-blind, placebo-controlled, multi-centre trial to assess the safety and efficacy of RP5063 in subjects with an Acute Exacerbation of schizophrenia or schizoaffective disorder	II	Globally 228 India 114	<ol style="list-style-type: none"> <li>1. Dr. Mahedru Ramesh Kumar, Mahendru Psychiatric Centre, Kanpur, UP</li> <li>2. Dr. Adarsh Tripathi , CSM Medical University, Lucknow , UP</li> <li>3. Dr. Chandrashekar H. Department of Psychiatric, Victoria Hospital, Bangalore</li> <li>4. Dr. John Pulikaparambil John NIMHANS Bangalore Karnataka</li> <li>5. Dr. Kota Suresh Kumar Shravani Mental Health &amp; Deaddiction Centre, Guntur, AP</li> <li>6. Dr. Sathianathen Ramanathan International Centre for Clinical Research in Mental Health &amp; Neurosciences , Chennai, TN</li> <li>7. Dr. Ravisha Thunga A. Manaswini Thunga Institute of Psychiatry &amp; Counselling, Mangalore, KA</li> <li>8. Dr. Satheesh Rao K.S Hegde Medical Academy, K.S Hegde Medical Sciences complex, Deralakatte, Mangalore, Karnataka</li> </ol>	17.08.2012
----	-----------	--------	------------	---------	---	----	---------------------------------	---	------------

42	CT/83/12	Ranolazine	GS-US-259-0147	KlinEra	A phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of ranolazine when to added to Metformin in subjects with Type 2 Diabetes Mellitus.	III	globally 400 India 200	<p>1. Dr. Badgandi Mohan Manipal Hospital, Airport Road, Bangalore.</p> <p>2. Dr. Mala Darmalingam Endocrinology &amp; Diabetes Research Centre, Bangalore, Malleshwaram, Karnataka. 3. Dr. Abhay Mutha, Diabetes Care and Research Centre, Pune.</p> <p>4. Dr. Ramanathan Balamurgan, Kovai Diabetes Speciality Centre &amp; Hospital, Ramnagar, Coimbatore.5. Dr. Chittrarajan S Yajnik, KEM Hospital, Rastha Peth, Pune.</p> <p>6. Dr. Kiran Pal Singh, Fortis Hospital, Mohali, Fortis City Center, Punjab.</p> <p>7. Dr. Sivagnanam Nallaperumal, Swamy Diabetes Centre, R.K. Mutt Road, Mandaveli, Chennai.8. Dr. K. M. Prasanna, The Bangalore Diabetes Hospital, 16/M, Thimmainah Road, Vasanthnagar, Bangalore.9. Dr. Sanjeev Ratnakar Phatak, DHL Research Centre, 2nd Floor, Ahmedabad.10. Dr. Darshan Banker, Banker's Heart Institute, Vadodara.</p> <p>11. Dr. Bansi Saboo, Dia Care- A Complete Diabetes Care Center, 1 &amp; 2, Gandhi Park, Near Nehrunagar Cross Roads, Ambawadi, Ahmedabad. 12. Dr. Rakesh Kumar Sahay, Osmania General Hospital, Afzalgunj, Hyderabad. 13. Dr. S. Srikanta, Jnana Sanjeevani Medical Center, J.P. Nagar Bangalore. 14. Dr. Ardhanareeshwaran Sharda, Endocrinology Diabetes Centre, 640, 1st stage Indiranagar Karnataka, Bangalore-560078. 15. Dr. Ashish Saxena, Diabetes and Heart Centre, Main Sunder Nagar Road, Ludhiana 16. Dr. Padmalatha Devi, Diabetomics India, Banjara Hills, Hyderabad. 17. Dr. Hansraj Alva, Vinaya Hospital and Research Centre, Karangalpady, Mangalore,18. Dr. Sanjay Reddy, Bangalore Diabetes Hospital, Bangalore, Karnataka.19. Dr. Subhankar Choudhury, IPGME &amp; R and SSKM Hospital, Kolkatta.</p> <p>20. Dr. Jayachri Shembalker, Getwell Hospitals and</p>	31.10.2012
----	----------	------------	----------------	---------	---	-----	---------------------------	---	------------

43	CT/192/11	Macitentan	AC-055C301	Clintec	Propective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safet and tolerability of Macitentan in patients with ischemic digital ulcers associated with systemic sclerosis	III	Globally 500 India 130	1. Sarvajeet Pal, Advance Rheumatology Centrre, First Floor, Kautilya, Besides Medinova Complex Somajiguda, Hyderabad 2. Dr. Sharath Chandra Moul Veeravalli, Krishna Instiute of Medical Science Ltd. 3. Dr. Debashish Danda, Dept. of immunology & Rheumatology, CMC, Vellore	3.04.2012
44	CT/207/11	Sitagliptin	MK-431-260-00	MSD	A Phase III, Multicentre, Randomized, double-blind, placebo-controlled clinical trial to study the safety and Insulin-Sparing efficacy of the addition of Sitagliptin in Patinets with Type 2 Diabetes Mellitus who have Inadeuate Gluycemic Control on Insulin Alone or in combination with Metformin	III	Globally 600 India 40	1. Shaikh Shela Sajid Akhtar,K.G.N. Research Institute, 9/10, Patel Aracde, 1st Floor, Opp. Sagar Hotel, Nagpada Junction, Mumbai 2. Dr. Sunil Surajprasad Gupta, Diabetes care & Research Cnetre, Lendra Park, Ramaspath, Nagpur 3. Sandeep Kumar Gupta, M.V. Hospital & Research Centre, Mandi Chowk, Lucknow-226003 4. Bandgar Tushar Ramkrishna, Research Health Institute In Dabetes Endocrinology & Metabolism, Dadasaheb Phalkee Road, Dadar (EAST), Mumbai	14.06.2012

45	CT/63/11	(I)Efavirenz/ Emtricitabine Tenofovir(II) Emtricitabine Tenofovir (III) Efavirenz (IV) Emtricitabine	A5274	BJ Medical college	Reducing Early Morality and Early Morbidity by Empiric Tuberculosis treatment Regimens	IV	globally 836 India 20	1. Vidya Mave, Clinical Reseerach Site Leader and Director, B.J. Medical College and Sassoon General Hospitals, Jai Prakash Narayan, Road, Pune	21.08.2012
----	----------	--	-------	-----------------------	---	----	--------------------------------	---	------------

46	CT/221/11	R04917838	NN25307	Quintiles	Phase III, multicentre, randomized, 12 weeks, double blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of Schizophrenia treated with antipsychotics followed by a 40 weeks double-blind, parallel-group, placebo-controlled treatment period	III	Globally 600 India 90	<ol style="list-style-type: none"> <li>1. Satheesh Rao, Centre for Psychiatric research, K.S. Hegde Medical Academy, Magalore, Karnataka</li> <li>2. Dr. Supriya Hegde, KMC Hospital, Attavar, Mangalore, Karnataka</li> <li>3. Dr. Dattatreyas Madhav Dhavale, Poona Hospital &amp; Research Centre, Sadashiv Peth, Pune</li> <li>4. Dr. Sandip Shah Hasmukhlal, Brij Psychiatry Hospital &amp; Muskaan Research Centre, Opp. Nimbalkar Chambers, Dandia Bazar, Vadodara</li> <li>5. Dr. Vaishal Nareshchandra Vora, Sneha clinic, Maninagar Char Rawsta, Maninagar Ahmedabad</li> <li>6. Dr. Mrugesh Dharnidharprasad Vaishnav, Samvedna Psychiatry &amp; Sex therapy Hospital, Below Karnavati Hospital building Ellisbridge, Ahmedabad</li> <li>7. Dr. Anil Kumar Tambi, Mental Health care &amp; Research, Malviya Nagar, Jaipur</li> <li>8. Dr. Manoj Kumar Sahu, Pt. JNM Medical College &amp; Dr. BR Ambedkar Hospital, Jail Road, Raipur</li> <li>9. Dr. Raksh Yadav, R.K. Yadav Memorial Mental Health &amp; De-addiction Hospital, B-6, Hanuman Nagar, Main Sirsi Road, Khatipura, Jaipur</li> <li>10. Dr. Pradeep Bhikhhalal Vaghasiya, Gujarat Institute of Psychological Science and Research Centre, Shreenath Complex, Umiya Vijay Road, Opp. Punitnagar-1, Ahmedabad</li> <li>11. Dr. Sundeep Dattatrya Jadhav, Manav Neuro Psychiatric Hospital Pvt Ltd, Saraswati Building, 1st floor, Santoshi Mata Road Kalyan (W)-421301</li> </ol>	12.07.2012
----	-----------	-----------	---------	-----------	--	-----	-----------------------------	---	------------

47	CT/68/11	CXA 201	CXA-cUTI-10-05	Pra	A Multicentre, Double-Blind, Randomized, Phase 3 Study to Compare the Safety And Efficacy of Intravenous Cxa-201 And Intravenous Levofloxacin In Complicated Urinary Tract Infection, Including Pyelonephritis.	III	Globally 776 India 200	<p>1. Dr. Arun Chawla, Professor, Kasturba Medical College &amp; Hospital, Dept. of Urology, Manipal-576104, Karnataka India</p> <p>2. Dr. Dinesh Jain, Associate Professor, Department of Medicine, Dayanand Medical College &amp; Hospital, Dept. of Medicine, 2nd Floor, New Tagore Nagar, Civil Lines, Ludhiana - 141001. Punjab. India.</p> <p>3. Dr. Apul Goel, Associate Professor, Chhatrapati Shahuji Maharaj Medical University, Dept. of Urology, Chowk, Lucknow-226003, Uttar Pradesh, India.</p> <p>4. Dr. Prakash Khetan, Principal Investigator, Shravan Hospital and Kidney Institute, 239, Nandanvan Main road, Nagpur-440009. India.</p> <p>5. Dr. Laxmi Chand sharma, Professor &amp; Head. SMS Medical College &amp; Attached Hospitals, Dept. of Nephrology, Sawai Ram Singh Road, JAipur-302004, Rajasthan, India.</p> <p>6. Dr. Manish Ahuja, Principle Investigator, Fortis Hospital- Mohali, Phase VIII, Sector 62, Mohali - 160062. Punjab. India</p> <p>7. Dr. Vipul Vaghjibhai Shah, Consultant Physician and Infectious Disease Specialist, Siddhivinayak Hospital, Balvatika-Maninagar Road, Maninagar, Ahmedabad-380008. Gujarat, India</p> <p>8. Dr. Sonal Dalal, Consultant Nephrologist, Gujarat Kidney Foundation, 4-5th floor, Shaival complex, Near Suvidha Shopping centre, Between Parimal crossing &amp; Mahalaxmi Char Rasta, Paldi, Ahmedabad - 380007. Gujarat-India.</p> <p>9. Dr. Mayank Rameshchandra Thakker, Chief Intensivist and Critical Care Specialist. Shree Giriraj Multispeciality Hospital, 150 Feet Ring road, 27-Navjyot Park Main Road, Amin Marg Cross Road, Rajkot-360005. Gujarat, India.</p> <p>10. Dr. Kapil Thakkar, M.S., DNB Urology (Nadiad), MNAMS Consulting Urologist &amp; Andrologist.</p>	11/8/2012
----	----------	---------	----------------	-----	---	-----	---------------------------------	--	-----------

48	CT/182/11	Simvastatin+A tenolol+ Ramipril+Hydr ochlorothiazid e+Aspirin+ Vitamin D	TIPS3	Cadila	A randomised, double-blind, placebo-controlled trial for the evaluation of a Polycap, low dose aspirin and vitamin D supplementation in primary prevention - The International Polycap Study 3 (TIPS 3)	III	Globally 5000	<ol style="list-style-type: none"> <li>1. Dr. Barraj Bosco, Trichy Diabetes Centre, Thillainagar, Trichy, Tamil Nadu</li> <li>2. Dr. Neeta R. Despandes, Belgaum Diabetes Centre, Belgaum, Karnataka</li> <li>3. Dr. Ganpathi, St.Johns Medical College hospital &amp; research Centre, Bangalore</li> <li>4. Dr. V. Mohan, Madras Diabetes Centre, Chennai</li> <li>5. Dr.J. Narendra Nanjappa, Life care, Shivamogga, Karnataka</li> <li>6. Dr. R.B. Panwar, SP Medical college, Bikaner, Rajasthan</li> <li>7. Dr. S.P. Kalantri, Mahatma Gandhi Institute of Medical Sciences, Wardha, Maharashtra</li> <li>8. Dr. Y Balaji, Shri Balaji Nursing Home, Adoni, kurnool (District) A.P</li> <li>9. Dr. Rajiv Gupta, Fortis Escots Hospital, Jaipur</li> <li>10. Dr. Ketan Mehta, Health harmony, Mumbai</li> <li>11. Dr. S. Anadaraja, Indra Gandhi Institute of Medical Sciences, Pondicherry, Puducherry</li> <li>12. Dr. kamal Sharma, Dr. Kamal Sharma Cardiologist Clinic, Ahmedabad, Gujrat</li> <li>13. Dr. Sunil Dwivedi, Vikram hospital, Bangalore</li> <li>14. Dr. Sandeep kumar Gupta, M.V. Hospital &amp; Research centre, Lucknow</li> <li>15. Dr. Hemang Baxi, Care Institute of Medical Sciences, Ahmedabad</li> <li>16. Dr. Sunil V.Sathe, Cadiac Care and Council centre, Pune</li> </ol>	2/5/2012
49	CT/102/11	Preladenant	P06153	Fulford	A phase III, 40 weeks, active controlled, double blind, double dummy extension study of preladenant in subject with moderate to severe Parkinson's disease	III	Globally 787 India 67	<ol style="list-style-type: none"> <li>1. Dr. Mahit batt, Kokilaben Dhirubhai Ambani Hospital &amp; Medical Research Institute, Andhari(W), Mumbai</li> <li>2. Dr. Asha Kshore, Sree Chitra Tirunal for Medical Science and Technology, Trivandrum</li> <li>3. Dr. Uday Muthane, Parkinson's &amp; Aging Reserach Foundation, Micro's Lab building , Kudhu Village, Hosur Main Road, Bangalao</li> <li>4. Dr. Charulata Sankhla, P.D. Hinduja National Hospital and MRC , Veer Savarkar, Mahim, Mumbai</li> <li>5. Dr. ANgamuthu Meena Kanikannan, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad</li> </ol>	19.06.2012

50	CT/106/11	Sativex (Oro mucosal spray)	GWCA1103	Pra	A two- part, placebo-controlled, study of the safety and efficacy of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patients with advanced cancer, who have inadequate analgesia even with optimized chronic opioid therapy.	III	Globally 756 India 227	<p>1. Dr. rakesh Taran, Consultant Medical Oncologist and Cancer Chemotherapist, Convenient Hospitals Ltd, (CHL)-Apollo Hospitals, A.B.Road, Near L.I.G Triangle, Indore 452008, Madhya Pradesh, India.</p> <p>2. Dr. Anish Maru, Senior Consultant Medical Oncologist, SEAROC Cancer Center, S.K. Soni Hospital, Sector 5 Main Sikar Road, Vidhyadhar Nagar, Jaipur 302013, Rajasthan, India.</p> <p>3. Dr. Pushplata Gupta, Senior Consultant, Dept of Anaesthesia and Palliative Care, Jawaharlal Nehru Marg, Near Saras Dairy, Malviya Nagar, Jaipur 302017, Rajasthan, India.</p> <p>4. Dr. Niti Raizada Narang, Medical Oncologist, A.M.H. Road, Indira Nagar, Bangalore 560038, Karnataka, India.</p> <p>5. Dr. Sushma Bhatnagar, Professor and HEad, Unit of Anaesthesiology, Pain and Palliative care, Dr. B.R.A. Institute Rotary Cancer Hospital, Room No 242, Ansari Nagar, New Delhi 110029, Delhi.</p> <p>6. Dr. Chetan Deshmukh, Medical Oncologist, Near Mhatre Bridge, Erandwane, Pune 411004, Maharashtra, India.</p>	12/10/2012
----	-----------	-----------------------------	----------	-----	--	-----	---------------------------------	---	------------

51	CT/12/12	Xprenor	MD2012/01 XP	Cinigen Ltd	A Phase II, randomized, multicentric, open-label, two arm study to determine the safety profile and establish the efficacy of Xprenor (buprenorphine oral lyophilisate) in comparison with Subutex® in opioid dependent patients	II	India	54	1. Dr. Roshan Jain, Cadabam's, Group of Psycho-Social Rehabilitation Centres Gulakamale Village, Near Kaggalipura 17th Mile Kanakapura Road, Post-Taralu, Bengaluru 560082, Karnataka, India.	8/31/2012
----	----------	---------	-----------------	-------------	--	----	-------	----	---	-----------

52	CT/159/11	Tamibarotene	TAMI-P2-NSCLC-01	Veeda	A randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects with Advanced Non-Small Cell Lung Cancer	IIb	Globally 140 India 42	<p>1. Dr. Sadashivudu Gundeti, Asst. Professor of Medical Oncology, Nizam's Institute of Medical Sciences (NIMS), Room 607, 6th floor, E Block, Panjagutta, Hyderabad-500082, Andhra Pradesh, India.</p> <p>2. Dr. Sivanesan Balasubramanian, G. Kuppuswam Naidu Memorial Hospital, Post Box No. 6327, Pappunaickenpalayam, Coimbatore- 641037, India.</p> <p>3. Dr. Minish Jain, Consultant Dept. of Medical Oncology, Noble Hospital, 153, Magarpatta City Road. Pune 411013, Maharashtra, India.</p> <p>4. Dr. Chiramana Haritha, Associate Professor, M.S. Patel Cancer Centre, Shree Krishna Hospital and MEDICAL Research Centre, Gokal Nagar, Karamsad - 388325. Gujrat, India.</p> <p>5. Dr. Gauri Shankar Bhattacharyya, Consultant Medical Oncologist and Clinical Hematologist, Orchid Nursing Home, P-17, CIT Road, Scheme VI M, Phoolbagan, Kolkata - 700054, West Bengal, India.</p> <p>6. Dr. Shailesh Arjun Bondarde, Consultant, Dept. of Medical Oncology, Shatabdi Super Speciality Hospital, Suyojit City centre, Opp Mahamarg Bus Stand Mumbai Naka, Nasik 422005, Maharashtra, India.</p>	1/30/2012
----	-----------	--------------	------------------	-------	--	-----	-----------------------------	---	-----------

53	CT/44/12	Doxorubicin-EMCH	INNO-206-P3-STS-01	GVK-Bio	Multicentre, randomized, open label phase 2b study to investigate the preliminary efficacy and safety of INNO-206 (Doxorubicin-EMCH) compared to doxorubicin in subject with Metastatic, Locally Advanced, or Unresectable soft tissue sarcoma	IIb	Globally 80 India 12	<p>1 Dr. Nalini Kilara M.S. Ramaiah Medical College and Hospitals, MSRIT Post, New BEL Road, Bangalore - 560054 Karnataka, India</p> <p>2 Dr. Minish Jain Noble Hospital, 1st Floor, Clinical Research Department, 153, Magarpatta City Road, Pune, Maharashtra India 411013</p> <p>3 Dr. Jyoti Bajpai Tata Memorial Hospital, Dr. Ernest Borges Marg. Parel (East), Mumbai - 400012 Maharashtra India</p> <p>4 Dr. Raju Chacko Christian Medical College, Department of Medical Oncology, Ida Scudder Road, Vellore, 532004 Tamilnadu, India</p> <p>5 Dr. Chirag Desai Hemato-Oncology Clinic, Vedanta Institute of Medical Sciences 1st Floor, Near Samved Hospital, Navrangpura, Ahmedabad - 380009, Gujarat, India</p> <p>6 Dr. Rajesh Grover Delhi State Cancer Institute, Dilshad Garden, New Delhi, 110095 Delhi India</p> <p>7. Dr. Rajnish Nagarkar Curie Manavata cancer centre, opposite Mahamarg Bus Stand, Mumbai Naka, Nashik-422004, Maharashtra</p> <p>8. Dr. Anish Maru SEAROC Cancer Centre, S K Soni Hospital, Sec 5 vidhyanagar, Main Sikar Road, Jaipur</p> <p>9 Dr. Sachin Hingmire Jehangir Clinical Development centre Pvt Ltd. Jahangir Hospital Premises, 32 Sassoon Road, Pune-411001</p>	18.09.2012
----	----------	------------------	--------------------	---------	--	-----	-------------------------	--	------------

54	CT/101/12	BIBF 1120	1199.93	Boehringer	An open label extension study trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF)	III	India-40 Globally-750	<ol style="list-style-type: none"> <li>1. Dr. Zarir Udawadia P.D. Hinduja National Hospital, Maham(W) Maharashtra</li> <li>2. Dr. Srikanth Krishnamurthy PSG Hospital, Peelamedu, Coimbatore, Tamilnadu</li> <li>3. Dr. Alope Ghoshal National Allergy Asthma Bronchitis Institute, 11/3, Dr. Biresh Guha street Kolkata</li> <li>4. Dr. Virendra Singh SMS Medical College and Hospital, Dhanvantari, OPD Block, Jaipur, Rajasthan</li> <li>5. Dr. Parthiv Mehta Mehta Hospital and Cardiopulmonary, Near Doordarshan Kendra, Drive Road, Thaltej, Ahmedabad</li> <li>7. Dr. Sathish K.S. Chest and Maternity Centre, Rajajinagar, Bangalore, Karnataka</li> <li>8. Dr. Parag Khatavkar K.E.M Hospital, Pune, Rasta Peth, Maharashtra</li> <li>9. Dr. Mahendra Kawedia Jehangir Clinical development centre Pvt. Ltd, Sasson Road Pune, Maharashtra</li> <li>10. Dr. Ashish Kumar Asthma Bhawan, Indian Asthma care Society, R-3, Sector 6, Vidyanagar, Jaipur</li> </ol>	07.12.2012
----	-----------	-----------	---------	------------	--	-----	--------------------------	--	------------

55	CT/204/11	Brinzolamide 1% &Brimonidine 0.2% Ophthalmic suspension	C-10-041	Alcon Laboratories (India)	Efficacy and safety of Brinzolamide 10mg/mL / Brimonidine 2mg/mL eye drops, suspension compared to Brinzolamide 10mg/mL eyedrops, suspension plus Brimonidine 2mg/mL eye drops, solution in patients with Open- Angle Glaucoma or Ocular Hypertension	III	Globally 820, India 100	1. Dr. Shobha Kulai Kini, Vasan Eye Care Hospital, Salem, Tamil Nadu 2. Dr. Manju R Pillai, Deptt of Glaucoma Services, Arvind Eye Hospital and Post Graduate Institute of Ophthalmology, Madurai, Tamil Nadu 3. Dr. Harsha B L Rao, L V Prasad Eye Institute, Hyderabad, Andhra Pradesh	3.04.2012
----	-----------	--	----------	----------------------------------	--	-----	----------------------------	--	-----------

56	CT/238/11	Ceftazidimeav ibactam	Ceftazidime	PPD	<p>A phase III , randomized, multicentre, double- blind, double dummy, parallel group, comparitive study to determine the efficacy, safety and tolerability of Ceftazidime Avibactam (CAZ-AVI) plus Metronidazole versus Meropenem in the treatment of complicated Intra- Abdominal Infections (cIAs) in hospitalized adults</p>	III	Globally 1106 India 165	<p>1. Dr. Ramesh M K , Bangalore Medical College and Research Institute, Bangalore 2. Dr. Ashwin Dhanrajji Porwal, Inamdar Multispeciality hospital, Pune, Maharashtra 3. Dr. Ajit Naniksingh Kukreja, Ratandeep surgical hospital and endoscopy clinic, Ahmedabad, Gujarat 4. Dr. Kartikeyan Chellappan, Noorul Islam Institute of Medical Sciences and research foundation, Thiruvananthapuram, Kerala 5. Dr. Bhatnagar Manish Surajprakash, Sterling hospital, Ahmedabad, Gujarat 6. Dr. Choudhary Ashmeet, Bombay hospital Indore, Madhya Pradesh 7. Dr. Kalambe Bharat Gorakhnath, KEM hospital Research Centre, Pune , Maharashtra 8. Dr. Duttaroy Dipesh Dilipkumar, Deptt of surgery, Medical College and Sir Sayajirao General Hospital Baroda, Vadodara, Gujarat 9. Dr. Prithi Rodgers, Sahyadri Hospital, Pune, Maharashtra 10. Dr. Vijaykumar HM, MS Ramaiah Medical College and hospital, Bangalore, Karnataka 11. Dr. Jaikish Jayaraj, PVS hospital, Calicut, Kerala 12. Dr. Puduccode Parameshwaran Sethu Babu, Sai Vani hospital, Hyderabad, Andhra Pradesh 13. Dr. Thodana Vadivelu Sekar, Madurai 14. Dr. Goel Amitabh, Choithram Hospital and research centre, Indore , Madhya Pradesh 15. Dr. Sathpal Singh, Deptt of surgery, Dayanand Medical College and Hospital, Ludhiana, Punjab 16. Dr. Sandeep Tiwari, Chhatrapati Shahuji Maharaj Meical University, Lucknow, UP 17. Dr. Kaushal Yogendrabhai Vyas, Sheth Vadilal Sarabhai General Hospital, Ahmedabad, Gujarat 18. Dr. Hariprasad TR, K R Hospital, Bangalore, Karnataka 19. Dr. Saniav Singhal, Mahatma Gandhi Medical</p>
----	-----------	--------------------------	-------------	-----	--	-----	-------------------------------	---

57	CT/124/11	S-equal(AUS-131)	AUS-CT04	Novotech Clinical Research Ltd	Randomized, double blind, multicentere, placebo controlled, Proof-of Concept trial to assess the efficacy and safety of 4 weeks treatment with AUS-131 (S-equal) on Benign Prostatic Hyperplasia	Ila	Globally 124 India 50	<ol style="list-style-type: none"> <li>1. Dr. Ajit Saxena, Indraprastha Apollo Hospital, New Delhi.</li> <li>2. Dr. Shirish D Yande, Ruby Hall Clinic, Pune, Maharashtra,</li> <li>3. Dr. Sher Singh Yadav, SMS Medical Hospital, Jaipur</li> <li>4. Dr. Sujata K Patwardhan, G S Medical College, Mumbai, Maharashtra,</li> <li>5. Dr. Nayan Kumar Mohanty, VMCC and Safdarjung HOspital, Delhi,</li> <li>6. Dr. Sham Abdul Kadar Eqbal, Inamdar Multispeciality hospital, Pune, Maharashtra</li> <li>7. Dr. Mohan Adhyam, St Johns Medical College and hospital, Bangalore,</li> <li>8. Dr. H K Nagaraj, M S Ramaiah Medical College and hospital, Bangalore,</li> <li>9. Dr. Sunil P Shenoy, A J Hospital and research Centre, Mangalore,</li> <li>10. Dr. Jayank Desai, Samved Hospital, Ahmedabad, Gujarat.</li> </ol>	13.4.2012
58	CT/103/11	YKP3089	YKP3089C013	Quintiles	A phase II, Multicentre, double blind, randomized, adjunctive placebo controlled trial with an open label extension to evaluate the efficacy and safety of YKP3089 in subjects with treatment resistant partial onset seizure	II	Globally 200 India 70	<ol style="list-style-type: none"> <li>1. Dr. Jagaralpudi Murali Krishna Murthy, Care hospital, Deptt of Neurology, Hyderabad, Andhra Pradesh,</li> <li>2. Dr. Shankara Nellikunja, Mallikatta Neuro Centre, Mangalore, Karnataka,</li> <li>3. Dr. Puneet Aggarwal, Max Super Speciality Hospital, New Delhi,</li> <li>4. Dr. R Srinivasa, Deptt of Neurology, MS Ramaiah medical college and hospital, Bangalore, Karnataka,</li> <li>5. Dr. Subhash Chandra Mukherjee, Nightingale hospital, Kolkata, West Bengal,</li> <li>6. Dr. Sattaluri Sitajayalakshmi, Krishna Institute of Medical Sciences, Andhra Pradesh,</li> <li>7. Dr. Vikram Sharma, St. Theresa's General Hospital, Hyderabad, Andhra Pradesh</li> </ol>	7.3.2012

59	CT/09/12	PF-04171327	A9391010	Pfizer	A phase II randomized, double blind assessment of efficacy and safety of PF-04171327 (1,5,10,15 mg dose daily) compared to 5mg and 10 mg Prednisone daily and placebo daily in subjects with rheumatoid arthritis over an 8 week period of tapering of study drug.	II	Globally 315 India 30	<ol style="list-style-type: none"> <li>1. Dr. Manoj Kumar Venkataiya Honnakere, Shridi Sai Hospital, Bangalore, Karnataka,</li> <li>2. Dr. Sarath Chandra Mouli Veravalli, Krishna Institute of Medical Sciences, Secunderabad, Andhra Pradesh,</li> <li>3. Dr. Puneet Kumar, Chhatrapati Shahuji Maharaj Medical University, Lucknow, UP,</li> <li>4. Dr Jugal Kishore Kadel, Mahavir Hospital and Research centre, Hyderabad, Andhra Pradesh</li> <li>5. Dr. Srikantiah Chandrashekara, Chan RE Rheumatology and Immunology centre and research, Bangalore, Karnataka</li> </ol>	29.4.2012
60	CT/18/12	PF-05208752	B1801031	Pfizer	A multicentre, 12 week double blind placebo controlled randomized study of Etanercept on a background NSAID in the treatment of adult subjects with non radiographic axial Spondyloarthritis with a 92 week open label extension	III-b	Globally 200, India 20	<ol style="list-style-type: none"> <li>1. Dr. Jugal Kishore Kadel, Mahavir hospital and Research Centre, Deptt of Rheumatology, Hyderabad, Andhra Pradesh,</li> <li>2. Dr. Sarath Chandra Mouli Veeravalli, Krishna Institute of Medical Sciences, Secunderabad, Andhra Pradesh,</li> <li>3. Dr. Vineeta Shobha, St. John's Medical College Hospital, Bangalore, Karnataka,</li> <li>4. Dr. Reena Sharma, Shalby Hospital, Ahmedabad, Gujarat,</li> <li>5. Dr. Sapan Pandya, Rheumatic Disease Clinic, Ahmedabad, Gujarat,</li> <li>6. Dr. Dharmanand Balebail Gopalakrishna, ChanRe Rheumatology Immunology centre and Research, Bangalore, Karnataka</li> </ol>	24.04.2012

61	CT/156/11	Armodafinil	C10953/3073	inVentiv	A double blind, placebo controlled, parallel group, fixed dose study to evaluate the efficacy and safety of Armodafinil treatment (150mg/day) as adjunctive therapy in adults with Major Depression associated with Bipolar I disorder	III		<p>1. Dr. Ranjivi Mahajan, Dayanand Medical college and hospital, Ludhiana, Punjab,</p> <p>2. Dr. Satheesh Rao, KS Hedge Medical academy, Mangalore, Karnataka,</p> <p>3. Dr. Nadukuru Nooka Raju, Maharishi Institute of Neuro-psychological Disorders, Visakhapatnam,</p> <p>4. Dr. Venu Gopal Janwar, Deva Mental Healthcare, Varanasi, UP,</p> <p>5. Dr. Jitendra Kumar Trivedi, Manobal Medical Research Centre, Lucknow, UP</p>	7.3.2012
62	CT/101/11	Fesoterodine	A6221094	Pfizer	A 14 weeks randomized, parallel group, placebo controlled, double blind, multicentre study of Fesoterodine 8mg in overactive bladder patients with sub-optimal response to Tolterodine 4mg ER	III	Globally 1990 India 150	<p>1. Dr. Prassana Venkatesh Matippa Kanthiraj, NU hospitals, Bangalore, Karnataka,</p> <p>2. Dr. Dr. Mallikarjuna Reddy Nalabolu, Hyderabad Institute of Neurology, Hyderabad, Andhra Pradesh,</p> <p>3. Dr. Kapil Thakkar, Excel hospital, Surat, Gujarat,</p> <p>4. Dr. Ravindra B Sabnis, Muljibhai Patel Urological hospital, Gujarat,</p> <p>5. Dr. Nagendranath Mishra, Kidney and Neurology hospital, Ahmedabad, Gujarat,</p> <p>6. Dr. Padmaraj Hedge, Kasturba hospital, Manipal</p> <p>7. Dr. Sathya Sirni Vasan, Ankur Healthcare, Bengaluru, Karnataka,</p> <p>8. Dr. Kandarp Parikh, Sterling hospital, Ahmedabad, Gujarat</p> <p>9. Dr. Rajeev Sood, RML hospital, New Delhi</p> <p>10. Dr. Hemant Ranganath Pathak, TN medical college and BYL Nair Ch. hospital, Mumbai</p> <p>11. Dr. Lakshminarayanappa Sreenivasa Murthy, Life Care clinic and research centre, Bangalore, Karnataka,</p> <p>12. Dr. Raghunath Sarakanur Krishnappa, Sri Venkateshwara hospital, Bangalore, Karnataka</p>	19.4.2012

63	CT/177/11	Tenofovir/Emtricitabin+Efavirenz	START	YRG care	A randomized, double blind, placebo controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV plus two Nucleotide Reverse Transcriptase inhibitors (N(t)RTI) in Antiretroviral Naïve HIV infective individuals over 96 weeks	III	Globally 630 India 100	1. Dr. Nagalingeswaran Kumarasamy, YRG care medical centre, Chennai	23.7.2012
64	CT/107/11	Sativex Oromucosal Spray	GWC0999	PRA	A multicentre, non comparative, open label extension study to assess long term safety of Sativex oromucosal spray (Sativex® Nabiximols) as adjunctive therapy in patients with uncontrolled persistent chronic cancer related pain	III	Globally-800 India-65	<ol style="list-style-type: none"> <li>1. Dr. Niti Razada Narang, Chinmaya Mission hospital, Bangalore, Karnataka</li> <li>2. Dr. Sushma Bhatnagar, AIIMS New Delhi.</li> <li>3. Dr. Pushpulata Gupta, Bhagwan Mahavir Cancer hospital, and research centre, Jaipur, Rajasthan,</li> <li>4. Dr. Dr. Rakesh Taran, Convenient hospital, Indore, Madhya Pradesh,</li> <li>5. Dr. Dr. Anish Maru, SEAROC Cancer centre, Jaipur, Rajasthan,</li> </ol>	19.4.2012

65	CT/136/11	PF-00299804	A7471609	Pfizer	A randomized, double blind, phase III efficacy and safety study of PF-00299804 versus Erlotinib for the treatment of advanced non small cell lung cancer following progression after , or intolerance to , atleast one prior chemotherapy	III	Globally-800 India-100	<ol style="list-style-type: none"> <li>1. Dr. Amit Agarwal, International Oncology Centre, Fortis hospital, Noida,</li> <li>2. Dr. Ganesha Dev Vashishta, Rajalaxmi multispeciality hospital, Bangalore, Karnataka,</li> <li>3. Dr. S N Karandikar, Ruby hall clinic, Pune, Maharashtra,</li> <li>4. Dr. Sandeep Batra, Medanta Medicity, Gurgaon, Haryana,</li> <li>5. Dr. Unmesh Takalkar, Kodlikeri Memorial hospital, Aurangabad, Maharashtra</li> <li>6. Dr. Niti Raizada Narang, Sri Venkateshwara hospital, Bangalore, Karnataka,</li> <li>7. Dr. Poonam Patil, Manipal hospital, Bangalore,</li> <li>8. Dr. Asis Mukhopadhyay, Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata, West Bengal,</li> <li>9. Dr. Kumar Prabhash, Tata Memorial hospital, Mumbai,</li> <li>10. Dr. Digamber Behera, LRS institute of TB and Respiratory disease, New Delhi,</li> <li>11. Dr. Chirag Jyotiker Desai, VEDANTA institute of medical sciences, Ahmedabad, Gujarat,</li> </ol>	30.1.2012
66	CT/207/10-DCG(I)	Gentian Violet	A5265	BJ Medical College	A Phase-3, open label, randomized, assessment blinded CT to compare the safety & efficacy of topical gentian violet to that of Nystatin oral suspension for treatment of oropharyngeal candidiasis in HIV-1 infected participants.	III	India 25	Dr. Dileep Kumar, B.J. Medical College & Sassoon general Hospital	1/11/2012

67	CT/169/10	MK-6621	010-01	MSD	A Phase-3, prospective, randomized, double blind, placebo controlled, multicenter study to evaluate the efficacy & safety of MK6621 in patients with Arterial Fibrillation	III	Globally 615 India 220	1. Dr. Hemant Thacker, Bhatia Hospital, Mumbai, 2. Dr. Sen Gupta, Sen Gupta Hospital, Nagpur, 3. Dr. Shomu Bora, Baroda Heart Institute & Research Center, Gujrat, 4. Dr. Sandeep Kumar Gupta, MV Hospital, Lucknow 5. Dr. Anil Saxena, Escorts Heart Institute, New Delhi, 6. Dr. Narendra J., Nanjappa Hospital, Shimoga, 7. Dr. JPS Sawhney, Sir Gangaram Hospital, New Delhi, 8. Dr. AG Ravikishor, Naryana Hridayalaya Bangalore, 9. Dr. Poonam Lave, Avanti Nagpur, 10. Dr. Anup Gupta, Sterling Hospital, Ahemdabad, 11. Dr. Rajesh Jain, CHL Apollo Indore, 12. Dr. Mahesh Fulwani, SKH Hospital, Nagpur	2/5/2012
68	CT/89/11	Nilotinib		Novartis	Extending Molecular Responses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (ENEST xtnD)	IIIb	Globally 400 India 25	1. Dr. Thirumalai Raj Raja, Apollo Speciality Hospital, Chennai, 2. Dr. Shashikant Janardan Apte, Sahyadri Clinical Research & Development Center, Pune	30/1/12
69	CT/155/10	0	ES-ORS-2	Christian Medical College	Esterified Starch & oral rehydration solution as a treatment for acute infectious diarrhoea	II	Total 100	1. Dr. B.S.RamaKrishna, Christian Medical College, Vellore	24/4/12
70	CT/227/11	PF-03049423	A9541004	Pfizer	A Phase-2, multicenter, randomized, double blind, placebo controlled study of safety & efficacy of PF-03049423 in subjects with ischemic stroke	II	Globally 200 India 25	1. Dr. Chandra Sekhar Reddy, Care Hospitals, Hyderabad, 2. Dr. Anand Alurkar, KEM Hospital & Research Center, Pune, 3. Dr. Puneet Agarawal, Max Super Speciality Hospital, Saket	9/5/2012

71	CT/01/12	FST 100	FST100-AVC-004	Excel Life Sciences	A Proof of Concept, multicenter, randomized, double-masked study to evaluate the clinical efficacy & safety of FST-100 (0.1% Dexamethasone & 0.6% PVP-Iodine) Ophthalmic suspension in the treatment of acute adenoviral conjunctivitis	II	Globally 308 India 176	<ol style="list-style-type: none"> <li>1. Dr. Umang Mathur, Dr. Shroff's Charitanie Eye Hospital, New Delhi,</li> <li>2. Dr. Uma Sridhar, ICARE Eye Hospital &amp; Post Graduate Institute , Noida,</li> <li>3. Dr. Chirag Bhatt, Susrut Eye Foundation &amp; Research Center, Kolkatta,</li> <li>4. Dr. Jayangshu Sengupta, Priyamvada Birla Aravind Eye Hospital, Kolkatta,</li> <li>5. Dr. I.S.Murthy, LV Prasad Eye Institute, Vishakhapatnam,</li> <li>6. Dr. Vinay R.Murthy, Prabha Eye Clinic &amp; Research Center, Bangalore,</li> <li>7. Dr. Anand Balasubramaniam, Sankara Eye Hospital, Bangalore,</li> <li>8. Dr. Veeresh P.Akki, Dr. Agarwal's Eye Hospital, Bangalore,</li> <li>9. Dr. Arjun Ahuja, Seth GS Medical College &amp; KEM Hospital, Mumbai,</li> <li>10. Dr. Shilpa Joshi, HV Desai Eye Hospital, Pune</li> </ol>	3/4/2012
72	CT/122/11	CD0271 0.1 % gel & CD0271 0.3 % gel	RD.03.SPR.40 164 E	CIDP	Assessment of efficacy & safety of CD02710.1% gel (Adapalene 0.1%) & CD02710.3% gel (Adapalene0.3%) versus vehicle of CD0271 in the treatment of acne & acne induced post inflammatory hyperpigmentation	Ila	Globally 40 India 20	<ol style="list-style-type: none"> <li>1. Dr. Sah Gaurang Krishna, CIDP Biotech India Pvt Ltd, New Delhi,</li> </ol>	4/1/2012

73	CT/87/11	Eprotriome	KBT009	Medpace	A placebo controlled, double blind, randomized, parallel group, long term Phase III trial assessing the safety and efficacy of 50µg and 100µg/day of eprotriome in patients with heterozygous familial hypercholesterolaemia who are on Optimal Standard of care	III	Globally 630 India 45	1. Dr. Vijay k Chopra, Medanta The medicity, Gurgaon, 2. Dr. Subramanyam K, Justice K. S. Hegde Charitable Hospital, mangalore, 3. Dr.J.P.S. Sawhnay, Sir Ganga Ram Hospital, New Delhi, 4. Dr. L. Sreenivasa Murthy, Life care Clinic and research centre, Bangalore, 5. Dr. Abraham Oomman, Apollo Hospitals, Chennai.	24/01/12
74	CT/210/11	(I) Riyataz (II) stocrin(III) Truvada (IV) Norvir (V) Combivir (VI) Kaletra/Aluvia (VII) Isentess (VIII) Epzicom (IX) Prezista	START:001	Y R G care	A multicenter, US Domestic and International trial of the International Maternal pediatric Adolescent AIDS clinical trials (IMPAACT) Group,"	III	Globally 400 India 125	1. Dr. Nagalingeswaran Kumarasamy, YRG Care Medical Center, Chennai	9/5/2012
75	CT/208/11	(I) Atripla (II) Truvada (II) Emtriva (III) Viread (IV) Stocrin		Y R G care	A5274/remember " Reducing early mortality & early morbidity by empiric tuberculosis treatment regimens"	IV	Globally 836 India 50	1. Dr. Nagalingeswaran Kumarasamy, YRG Care Medical Center, Chennai	21/8/12

76	CT/52/12	Afatinib	1200.125	Boehringer	A randomized, open label phase III trial of Afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second line therapy following first line platinum based chemotherapy	III	Globally 800 India 60	<ol style="list-style-type: none"> <li>1. Dr. Anita ramesh, Sri Ramchandra Medical centre, TamilNadu,</li> <li>2. Dr. Sivanesan Balasubramanian, G. Kuppuswamy naodu Memorial Hospital, Coimbatore,</li> <li>3. Dr. Krishna Prasad, Arigya Multi speciality Clinica, Mangalore,</li> <li>4. Dr. Anand B. pathak, Cancer Care Clinic &amp; Hospital, Nagpur,</li> <li>5. Dr. Shekhar Gowda patil, HCG Bangalore Institute of Oncology, Bangalore,</li> <li>6. Dr. Naidu Norman Bethune, Yashoda Hospital, Andhra Pradesh,</li> <li>7. Dr. Srinivasan Venkatesan, Dr. kamakshi Memorial Hospital, Chennai,</li> <li>8. Dr. S. Subramanian, V S Hospital, TamilNadu,</li> <li>9. Dr. Chirag Jyotikar Desai, Hemato-Oncology Clinic, Ahmedabad,</li> <li>10. Dr. Kirushna Kumar, Meenakshi Mission Hospital &amp; research Centre, Tamil Nadu,</li> <li>11. Dr. Niti Raizada narang, Vikram Hospital, bangalore,</li> <li>12. Dr. Minish Jain, Ruby hall Clinic, Pune,</li> <li>13. Dr. Chiramana Haritha, M S patel cancer centre, Gujarat,</li> <li>14. Dr. Kumar Prabhash, Tata Memorial Hospital, Maharashtra,</li> <li>15. Dr. SVSS Prasad, Apollo Hopsital, Hyderabad,</li> <li>16. Dr. Chanchal Goswami, B P Poddar hospital &amp;</li> </ol>	10/9/2012
77	CT/55/12	Solifenacin Succinate	905-CL-047	PPD	A Phase III Open Label, Baseline controlled, Multicenter, sequential dose Titration study to assess the long term efficacy and safety, and the Pharmacokinetics of Solifenacin Succinate Suspension in patients from 5 to less than 18 years of age with Neurogenic Detrusor Overactivity	III	Globally 74 India 17	<ol style="list-style-type: none"> <li>1. Dr. Shobha Lal Sukhdarshan, Himalayan Institute of Medical Sciences, Dehradun,</li> <li>2. Dr. Apul Goel, Chhatrapati Shahuji Medical University, Lucknow,</li> <li>3. Dr. Rajeev Sood, Dr. Ram Manohar Lohia Hospital &amp; PGIMER, New Delhi</li> </ol>	7/12/2012

78	CT/02/12	Dalcetrapib (R04607381)	NC25608	Quintiles	A Phase III b Multi center, double blind, placebo controlled, parallel group study to evaluate the effect of dalcetrapib 600mg on cardiovascular events in Adult patients with Stable Coronary heart Disease, CHD Risk Equivalents ar at elevated risk for Cardiovascular Disease	IIIb	Globally 20000, India 2400	1. Dr. Aniket Puri, Chattrapati Shahuji Maharaj Medical University, Lucknow, 2. Dr. Vinod Vijan, Vijan Cardiac & Critical care Center, Nashik, 3. Dr. Sudha VidyaSagar, Kasturba Hospital, Karnataka, 4. Dr. Hemant P. tahacker, Bhatia Hospital, Maharashtra, 5. Dr. Aravind Sosale Ramachandra Diacon Hospital, Bangalore, 6. Dr. AG. Ravishankar, K R Hopsital, Mysore Medical College & Research Institute, Karnataka, 7. Dr. Nalini Shah, Seth G. S. Medical College & K. E. M Hospital, Parel, Mumbai, 8. Dr. Shantanu Pradeep Sengupta, Sengupta Hospital & Research Institute, Nagpur, 9. Dr. Mukesh Kumar Sarna, Monilek Hospital & Research Center, Jaipur, 10. Proddutur Naveen Chander Reddy, Medicity Hospitals, Hyderabad, 11. Rajendra Kumar Premchand, Krishna Institute of Medical Sciences, Secunderabad, A.P., 12. Dr. Nitin Suresh Patki, Deenanath Mangeshkar Hospital & Research Center, Pune, 13. Dr. Mohanan Padinhare Purayil, Westfort Hi-Tech Hospitals Ltd., Kerala, 14. Dr. Anoop Mishra, Fortis Ft. Lt. Rajan Dhall Hospital, New Delhi, 15. Dr. Gaurav Minocha, Pushpanajali Crosslay Hospitals, Ghaziabad, 16. Dr. Sailesh Lodha, DEAR Foundation, Jaipur, 17. Dr. K.M.Prasanna Kumar, Bangalore Diabetes Hospital, Bangalore, 18. Dr. Harish Kumar, Amrita Institute of Medical Sciences, Kerala, 19. Dr. Kulkarni Ravindra Laxman, Ahwin's Medical Foundation's Moraya Multispecility Hospital, Pune, 20. Dr. Veerappa Annasaheb Kothiwale, KLES Dr. Prabhakar Kore Hospital & Medical Research Center, Belgaum, 21. Dr. Ravi Kishore A.G., Narayana Hrudayalaya Hospitals, Bangalore, 22. Dr. Johnny Joseph, Caritas Hospital, Kerala, 23. Dr. Jaganmani Sreekanth, Apollo Hospitals, Hyderabad, 24. Dr. Sunil Surajprasad Gupta, Diabetes Care n Research Center Pvt Ltd., Nagpur, 25. Sandeep Kumar Gupta, M.V. Hospital &	9/5/2012
79	CT/27/12	DEB025	CDEB025 A2312	Novartis	A multi center 3-year follow up study to assess the durability of Sustained Virologic response in Alisporivir treated chronic Hepatitis C patients	III	Globally 2000 india 83	1. Dr. Ajit Sood, Dayanand Medical College & Hospital, Ludhaina, 2. Dr. S. K. Sarin, Institute of Liver & Biliary Sciences, New Delhi, 3. Dr. Samir Mohindra, Sanjay gandhi Post Graduate Instituteof Medical Sciences, Lucknow, 4. Dr. Samir Shah, Diwaiiben Mohanlal Mehta Charitable trust, Mumbai, 5. Dr. Kaushal Madan, Medanta The Medicity, Gurgaon, 6. Dr. B. Prabhakar, Osmania General Hospital, Hyderabad.	5/10/2012

80	CT/28/12	DEB025	CDEB025A23 12	Novartis	A multi center 3-year follow up study to assess the viral activity in patients who failed to achieve Sustained Virologic response in Alisporivir treated chronic Hepatitis C patients	III	Globally India 29	650	1. Dr. Ajit Sood, Dayanand Medical College & Hospital, Ludhaina, 2. Dr. S. K. Sarin, Institute of Liver & Biliary Sciences, New Delhi, 3. Dr. Samir Mohindra, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, 4. Dr. Samir Shah, Diwaliben Mohanlal Mehta Charitable trust, Mumbai, 5. Dr. Kaushal Madan, Medanta The Medicity, Gurgaon.	4/10/2012
81	CT/21/12	Sitagliptin	MK-0431A-170-00	MSD	A phase III multicenter, double blind, randomized, placebo controlled clinical trial to evaluate the safety and efficacy of MK-0431A in Pediatric patients with Type 2 Diabetes mellitus	III	Globally India 50	240	1. Dr. Sunil Gupta, Diabetes Care n Research Centre, Nagpur, . Dr. Shreerang Godbole, Instride, Pune, 3. Dr. Bangalore raja, Cosmopolitan Medical Centre, Bangalore, 4. Dr. Dinesh Dhanwal, Maulana Azad Medical College and Associated Lok Nayak Hopsital, Bangalore, 5. Dr. Sarika Prasad, Mysore Clinical research, Aadithya Adhikari Hospital, Mysore.	31/08/12
82	CT/17/12	Mipomersen	MIP0380101 1	Sanofi	A Phase 3, randomized, Double blind, Placebo controlled Parallel group study to asses the safety and efficacy of two different Regimens of Mipomersen in patients with Familial Hypercholesterolemia and Inadequately controlled Low-Density Lipoprotein Cholesterol	III	Globally India 40	480	1. Dr. Vidhyut jain, Chotiram Hospital & research centre, Madhya Pradesh, 2. Dr. Harinder Bali, Fortis Hopsital, Mohali, 3. Dr Sandeep Kumar Gupta, M. V. Hospital & Research Centre, Lucknow, 4. Dr. Peeyush Jain, Escorts Heart Institute & Research centre, New Delhi.	19/09/12

83	CT/35/12	Valacyclovir	Exposure to HSV-V and Cognitive Impairment	Dr. Smita N. Deshpande	Valacyclovir augmentation for cognitive and functional remediation in Schizophrenia : replication and extension	An Institutional Study	68	1. Dr. Smita N. Deshpande, Dr. Ram Manohar Lohia Hospital, New Delhi.	9/5/2012
84	CT/39/12	CP-690,550	A3921095	Pfizer	A multicenter, randomized, double-blind, placebo controlled, parallel group study of oral CP-690,550 as an induction therapy in subjects with moderate to severe Ulcerative Colitis	III	Globally 545, India 75	1. Prof. Abhijit Chandra, Dept. of Surgical gastroenterology, Chhatrapati Shahuji Maharaj medical University, Lucknow, 2. Dr. Bhabadev Goswami, Dispur hospital, Guwahati, 3. Dr. mayank Kabrawala, Gastro Care gastro Intestinal Endoscopy centre, Gujarat, 4. Dr. Mukesh Kalla, S. R. Kalla memorial Gastro & general hospital, jaipur, 5. Dr. Chetan mehta, Gastrocare Clinic, Opp Dr Bharat Parekh Hospital, Rajkot, 6. Dr. Shrikant Mukewar, Midas Multispeciality Hospital, Nagpur, 7. Dr. Vinay Thorat, Poona Hospital & Research Centre, Pune	19/10/12

85	CT/04/12	Asenapine	P06384	Paraxel	A double blind, placebo controlled trial of Asenapine in the prevention of recurrence of a mood episode after stabilisation of an acute manic/mixed episode in subjects with Bipolar-I Disoredr (Phase-3b, Protocol P06384)	IIIb	Globally 550 India 79	1. Dr. Nagapurkar Umesh Sureshram, Sujata Birla Hospital & Medical Research Center, Nashik, 2. Dr. Dutt Lakshman Shankarlal, Shri Krishna Prasad Psychiatric Nursing Home & Research Center, Ahemdabad, 3. Dr. Chudgar Mahesh Vrajlal, Mental Illness Treatment Rehabilitation Foundation, Ahemdabad, 4. Dr. Satheesh Rao, Center for Psychiatric Research, Mangalore, 5. Dr. Gundugurti Prasad Rao, Asha Hospital, Hyderabad, 6. Dr. Ramesh Kumar Mahendru, Mahendru Psychiatric Center, Kanpur, 6. Dr. Hongally Chandrashekar, Victoria Hospital, Bangalore, 7. Dr. Vinay Laxmikantrao, Society for Psychiatric Update & Research, Aurangabad.	21/8/12
----	----------	-----------	--------	---------	---	------	-----------------------------	--	---------

86	CT/237/11	AMR101	AMR-10-10-0019	Pharmanet Clinical Services	A multicenter, prospective, randomized, double blind, placebo controlled, parallel group study to evaluate the effect of AMR101 on cardiovascular health & mortality in hypertriglyceridemic patients with cardiovascular disease or at high risk for cardiovascular disease (REDUCE-IT)- Reduction of cardiovascular events with EpA-Intervention Trial	III	Globally 7990, India 570	1. Dr. Santhosh Mysore Jayadev, St. John's Medical College Hospital, Bangalore, 2. Dr. Ramesh Srinivasiah Saligrama, Bhagwan Mahveer Jain Heart Center, Bangalore, 3. Dr. Malipreddi Bhaskara Rao, Care Hospital, Visakhapatnam, 4. Dr. Hathur Basavanagowdappa, JSS Medical College Hospital, Mysore, 5. Dr. Rajpal K.Abhaichand, G.Kuppuswamy Naidu Memorial Hospital, Coimbatore, 6. Dr. Arun Srinivas, Vikram Hospital, Mysore, 7. Dr. Hemant P.Thacker Bhatia Hospital, Mumbai, 8. Dr. Sathe Sunil Vasant , Cardiac Care & Counselling Center, Pune, 9. Dr. Ponangi Udaya Prashant, Global Hospitals, Hyderabad, 10. Dr. Byrapaneni Ramesh, Medwin Hospitals, Hyderabad, 11. Dr. Jitendra Pal Singh Sawhney, Dharma Vira Herat Center, Rajinder Nagar, New Delhi, 12. Dr. Nitin Kamalakar Ghaisas, Shatabdi Super Speciality Hospital, Nashik, 13. Dr. Veerapa Annasaheb Kothiwale, J N Medical College, Belgaum, 14. Dr. Atul Mathur, Escorts Heart Institute & Research Center, New Delhi, 15. Dr. Jugal Bihari Gupta, S.R.Kalla Memorial Gastro & General Hospital, Jaipur, 16. Dr. Mukesh Kumar Sarna, Monilek Hospital & Research Center, Jaipur, 17. Dr. Prafulla Gopinath Kerkar, KEM Hospital & Seth GS Medical College, Mumbai.	4/5/2012
87	CT/19/12	Axitinib	AP311736	Quintiles	A Randomized, double blind Phase 3 study of Adjuvant Axitinib vs Placebo in subjects at high risk of Recurrent RCC	III	Globally 598 India 132	1. Dr. Anil Mandhani, Sanjay gandhi Post Graduate Institute of Medical sciences, Lucknow., 2. Dr. Pisapati venkta lakshmi narasimha Murthy, Nizam's Institute of medical sciences, Hyderabad, 3. Dr. Tanveer M. Maksud, Bharat Cancer Hospital & research Institute, Surat, Gujarat, 4. Dr. Pavithran Keechilat, Amrita Institute of Medical Sciences & Research Center, Cochin, 5. Dr. Apul Goel, Chhatrapati Shahuji Maharaj Medical University, Lucknow, 6. Dr. Bhalchandra kashyapi, Jehangir Clinical development Centre Pune, 7. Dr. Minish mahendra jain, Rubi Hall Clinic, Pune .	10/9/2012

88	CT/190/11	CXA-201	CXA-clSI-10-09	Pharmaceutical Research	A Multicenter, double blind randomized, Phase 3 study to compare the Efficacy and safety of Intravenous CXA-201 with that of Meropenem in Complicated Intra-abdominal Infections	III	Globally 780 India 150	1. Dr. Sandeep Unnikrishnan, Chettinad Hospital and Research Institute, TamilNadu, 2. Dr. Jaikish Jairaj, PVS Hospital (P) Ltd., Calicut, 3.3. Dr. Sheetal Dhadphale, Ruby Hall Clinic, Pune, 4.4. Dr. Babu Krishnamurthy, Yashoda Hospital Secunderabad, 5.5. Dr. Rajnesh Chander Reddy, Apollo Hospitals, Hyderabad, 6.6. Dr. Kathikeyan Chellappan, Noorul Islam Institute of Medical Science (NIMS) & Research Foundation, NIMS MEDICITY, Trivendram, 7. 7. Dr. Rajesh Bhojwani, Santokba Durlabhji Memorial Hospital cum Medical Research Institute, Jaipur, 8. 8. Dr. Thodana Vadivelu Sekar, Apollo Speciality Hospitals, Madurai, 9. 9. Dr. Bharati Hiremath, M. S. Ramaiah medical College and Hospital, Bangalore, 10.10. Dr. Satish Dharap, SION Hospital, Mumbai, 11.11. Dr. Dipesh Dilipkumar Duttaroy, Medical College and Sir Sayajirao General Hospital, Baroda, 12.12. Dr. Sandeep Tiwari, Chhatrapati Shahuji Maharaj Medical University, Lucknow.	27/11/12
89	CT/53/11	Tasquinimod	10TASQ10	PPD	A phase 3 Randomized, Double blind, Placebo Controlled Study of Tasquinimod in Men with Metastatic Castrate-Resistant Prostrate cancer	III	Globally 1200 India 100	1. Dr. Gauri Shankar Bhattacharya, Orchid Nursing Home, Kolkatta, 2. Dr. Sunder Lal Tolani, Monilek Hospital and Research Centre, jaipur, 3. Dr. Kumar Prabhash, Tata Memorial Hospital, Dr. Earnest Borges Marg, parel, Mumbai, 4. Dr. Bhalachandra Dattatraya Kashyapi, Jehangir Clinical Development Centre Pvt Ltd, jehangir Hospital premises, Pune, 5. Dr. Ginil Kumar Pooleri, Amrita Institute of Medical Sciences, Health Care Education & Research, Kerala, 6. Dr. rajesh Bharani, Bombay Hospital, Indore, 7. Dr. Shailesh Arjun Bondarde, Shatabdi Superspeciality Hospital, Suyojit City centre, Nashik, Maharashtra, 8. Dr. Kim jacob Mammen, Christian Medical College & Hospital, Ludhiana.	30/01/12

90	CT/188/11	FTC+TDF+EFV	ACTG 5274	NARI	Reducing early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens	IV	Globally 16000 India 900	1. Dr. S P. Tripathi, NARI, Pune	21/08/12
91	CT/84/11	Seemore (EVP1001-1 Injection)	1001-1:122	Kentron	An Open label, baseline Controlled Single Dose study of the safety and Efficacy of SeeMore™ in patients being evaluated for Breast or Colon cancer	Ila	India 10	1. Dr. Gorijavolu Durga Prasad, Indo-American cancer Institute & Research Centre, Hyderabad, 2. Dr. Vijay kumar, C. S. M. Medical University, Lucknow	19/10/12
92	CT/73/11	Niacin/Laropiprant	MK-0524A-108	Covance	A 16 week, randomized, Placebo controlled study to evaluate the efficacy and safety of extended release Niacin/laropiprant in South and Southeast asians not on a Lipid Modulating Agent with Decreased high-density Lipoprotien Cholesterol and Low density lipoprotein Cholesterol at or below NCEP ATP III Goal	III	Globally 400 India 300	1. Dr. Hemant Thackar, Bhatia Hospital, Mumbai, 2. Dr. Hansraj Alva, Vinaya Hospital & Research Centre, Mangalore, 3. Dr. K. M. Prasannakumar, Medisys Clinisearch India Pvt ltd, Bangalore Diabetes centre, Bangalore, 4. Dr. jitendra pal Singh Sawhney, Sir Ganga Ram Hospital, New Delhi, 5. Dr. Jugal Bihari Gupta, S. R. Kalla Memorial Gastro and General Hospital, Jaipur, 6. Dr. Maddury Srinivasa Rao, Care Hospitals, Hyderabad.	19/07/12

93	CT/240/11	Eltrombopag	2010N10935 0_00	GSK	A Three part study of Eltrombopag in Thrombocytopenic subjects with Myelodysplastic syndromes or Acute Myeloid Leukemia	II	Globally 310 India 30	1.Dr.Joseph John, CMC Ludhiana, Ludhaina, 2. Dr. Biju George, CMC vellore, Vellore, 3. Dr. Samir Melinkeri, Deenanath Mangeshkar Hospital & Research centre, Pune, 4. Dr. Sandip C Shah, Hemato Oncology Clinic Ahmedabad, 5. Dr. Vijay Ramanan, Jehangir Clinical Development centre pvt ltd., Jehangir Hospital, Pune, 6. Dr. Seema Bhatwadekar, Global baroda Hopsital, Vadodra, 7. Dr. Satish A Kumar, Columbia Asia Hospital, Bangalore, 8. Dr. Soumya Bhattacharya, Apollo Gleneagles Hosptal, Kolkatta, 9. Dr. Senthil Rajappa, Indo-American Cancer Hospital & Research Institute, Hyderabad	19/04/12
----	-----------	-------------	--------------------	-----	---	----	--------------------------------	--	----------

94	CT/13/12	Linagliptin	1218.6	Boehringer	A randomized, double blind, double dummy, active-comparator controlled study investigating the efficacy and safety of Linagliptin co-administered with Metformin QD at evening time versus metformin BID over 14 weeks in treatment native patients with type 2 diabetes mellitus and insufficient glycaemic control	IV	Globally 80 India 70	1. Dr. Shailesh pitale, Pitale Diabetes and Hormone Centre, Nagpur, 2. Dr. Sanjeev Shah, Diabetes Action centre, Mumbai, 3. Dr. Rakesh parikh, Diamed Clinical Research Services Pvt Ltd, Jaipur, 4. Dr. Mohan Magdum, Jehangir Clinical Development centre, Pune, Maharashtra, 5. Dr. Ajay Dande, Dande Diabetes and heart care Centre maternity and Nursing Home, Aurangabad , maharashtra, 6. Dr. Arun Narayan, M.S. Ramaiah Medical College and Hospitals, Bangalore, 7. Dr. K.A.V. Subramanyam, Visakha Diabetes and Endocrine centre, Visakhapatnam, Andhra Pradesh, 8. Dr. Rajesh Gupta, Mahatma Gandhi medical College and Hospital, Jaipur, 9. Dr. Sunil Gupta, Diabetes Care n Research centre, Pvt Ltd, Nagpur, 10. Dr. Manojit Mukhopadhyay, Diabetes Clinic and Research Centre, Kolkata, 11. Dr. abhay Mutha, Diabetes care and Research Centre, Pune, 12. Dr. Girithara Gopalkrishnan, K.G. Hospital and Post Graduate Medical Institute, Coimbatore, 13. Dr. Tom Babu, Silverline Hopsital, Centre for Diabetes, Thyroid and Endocrinology, Kochi, Kerala.	11/7/2012
95	CT/151/11	Aripiprazole	31-10-273	Covance	A multicenter, randomized, double blind placebo controlled study evaluating the safety and efficacy of fixed dose once weekly oral Aripiprazole in children in children and Adolescents with Tourett's Disorder	III	Globally 192 India 25	1. Dr. Mahendru Ramesh Kumar, Mahendru Psychiatric Centre, Kanpur, 2. Dr. T.S. Sathyanarayana Rao MD, JS Medical College & Hospital, Mysore, 3. Dr. Shankara Nellikunja, Mallikatta Neuro centre, Mangalore, 4. Dr. Vrajesh P. Udani, P.D. Hinduja National Hospital & Medical Research Centre, Mumbai, 5. Dr. Venu Gopal Jhanwar, Deva Mental Health Care, Varanasi.	2/5/2012

96	CT/88/11	Fluticasone Furoate	HZ113782	Paraxel	A Clinical outcomes study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in subjects with moderate chronic obstructive pulmonary disease and a history of or at increased risk for cardiovascular disease	III	<p>1. Dr. Kannivelu Jagannath, Chennai Thoracic research Institute, Chennai, 2. Dr. Ajay Shah Navinchandra, Gujarat pulmonary &amp; Critical Care Clinic, Ahmedabad, 3. Dr. Krishnan Rajendran, Health and Research Centre, Trivandrum, Kerala, 4. Dr. Anthony Mesquita, Chest Hospital, Goa, 5. Dr. Ashish Deshmukh Shankarrao, CIGMA Institute of Medical Sciences, Aurangabad, Maharashtra, 6. Dr. Chenna Chandra Mohan, Omni Hospitals, Hyderabad, 7. Dr. Deepali Kamdar, Jaydeep hospital, Ahmedabad, 8. Dr. George Albert D'Souza, St. John's Medical College Hospital, Bangalore, 9. Dr. Karanam Gowrinath, Narayana Medical College and Hospital, Andhra Pradesh, 10. Dr. Mantri Sumant, Apollo Hospitals, Bangalore, 11. Dr. Boyilla Nagaraj, AXON Hospitals, Hyderabad, 12. Dr. Nitin Yashwant Abhyankar, Spirometry Clinic, Pune, 13. Dr. Prasad Sudhir, Aware Global Hospitals, Hyderabad, 14. Dr. Raj gautam Bhagat, Dr. Bhagat's allergy Asthma Clinic and Respiratory Care centre, Ahmedabad, 15. Dr. Ravindra Sarnaik, Leela More's Chest Clinic, Nagpur, 16. Dr. Ilangho Rex Peter, Apollo Hospitals, Chennai, 17. Dr. Sundeep Salvi, Chest Research Foundation, Pune, 18. Dr. Deshmukh Vikrant, Avanti Institute of cardiology Pvt Ltd, Nagpur, 19. Dr. Virendra Gupta, SMS Medical College and Hospital, Jaipur, 20. Dr. Vivek Gupta, Suretech Hospital and Research limited, Nagpur, 21. Dr. Yelchuri Ram, Ramakrishna Diabetes Research centre, Nellore, 22. Dr. Ashish Omprakash Goyal, Chaitanya Nursing Home, Pune, 23. Dr. Ashoka Horetti Gurusiddappa, Cauvery Hospital, Mysore, 24. Dr. Bhickchand Kapurchand Mutha, Dr. Mutha Hospital, Nashik, 25. Dr. Deepak Chauhan, Shri Nidan Hospital, Jaipur, 26. Dr. Judo Joseph Vachaparambil, West-Fort Hi-Tech Hospital, Kerala, 27. Dr. Kotnur Narayana Mohan Rao, M.S. Ramaiah Medical College and Hospital,</p>	7/3/2012
----	----------	---------------------	----------	---------	---	-----	---	----------

97	CT/85/12	AR-12286	AR-12286- CS206	Max neeman	A phase 2b double-masked, randomized, active controlled, dose response study assessing the safety and ocular hypotensive efficacy of AR-12286 in patients with elevated intraocular pressure for 3 months	II b	Only India - 195	1. Dr. Sunneta Dubey, Dr. Shroff's Charity Eye Hospital, New Delhi, 2. Dr. Subodh Kumar Sinha, Venu Eye Institute & research centre, New Delhi, 3. Dr. Rupali Chopra, Christian medical College & Hospital, Ludhiana, 4. Dr. Shrikant Dinkar Joshi, Deenanath Mangeshkar Hospital & Research Centre, Pune, 5. Dr. Sushma Tejwani, Narayana Health City, Bangalore, 6. Dr. Gowri J Murthy, Vittala International Institute of Ophthalmology, Bangalore, 7. Dr. Medha Prabhudesai, Prabhudesai Eye Clinic, Pune.	17/09/12
----	----------	----------	--------------------	------------	---	------	---------------------	--	----------

98	CT/96/11	BI 10773	E2080-G00-303	Boehringer	A Phase III randomized, double blind placebo controlled, parallel group, efficacy and safety study of BI 10773 (10mg, 25 mg), administered orally once daily over 12 weeks in hypertensive patients with Type 2 diabetes mellitus	III	Globally 816 India 120	1. Dr. Kasthuri A S, Bangalore Clinisearch, Karnataka, 2. Dr. Paramesh Shamanna, Medisys Clinisearch India Pvt Ltd., Karnataka, 3. Dr. Naga Jyothi Borra, Diabetomics India Pvt Ltd, Andhra Pradesh, 4. Dr. S R Aravind, Diacon Hospital, Karnataka, 5. Dr. Neeta R Deshpande, Belgaum Diabetes Centre, Karnataka, 6. Dr. C S Yajnik, KEM Hospital and Research Centre, 7. Dr. Hansraj Alva, Vinaya Hospital & Research Centre, Karnataka, 8. Dr. Puneet Rijhwani, Mahatma Gandhi Medical College and Hospital, Rajasthan, 9. Dr. Sunil Ganpatrao Ambulkar, Institute of Clinical Endocrinology & Diabetes Care Unit, 10. Dr. Shailesh Pitale, Pitale Diabetes & Hormone Centre, Maharashtra, 11. Dr. R Balamurgan, Kovail Diabetes Speciality Centre & Hospital, Tamil Nadu	7/3/2012
----	----------	----------	---------------	------------	---	-----	------------------------------	---	----------

99	CT/104/11	Perampanel	E2007-G000-332	PPD	A Double blind, randomized, placebo controlled, multicenter, parallel group study with an open label extension phase to evaluate the efficacy and safety of adjunctive Perampanel in Primary generalized Tonic-Clonic Seizures	III	Globally 164, India 28	1. Dr. Anshu Rohtagi, Sir Ganga Ram Hopsital, new Delhi, 2. Dr. Deepak Goel, Himalayan Institute of Medical Sciences, dehradun, 3. Dr. jagaralpudi Murali Krishna Murthy, Care Hospital, Department of Neurology, Hyderabad, 4. Dr. Vikram Sharma, St. Theresa's general Hospital, Hyderabad, 5. Dr. Shankara nellikunja, Mallikatta Neuro Center, Karnataka, 6. Dr. Sita Jayalakshmi Sattaluri, Krishna Institute of Medical Sciences, Hyderabad, 7. Dr. Srinivasa R, M. S. Ramaiah Medical College and Hospitals, Bangalore, 8. Dr. Atul Agarwal, Neurology Clinic, Lucknow, U.P.	7/3/2012
100	CT/98/11	Lucanthon	SPI-LUC-11-01	OncoRx	An international, multicenter, randomized, double blind placebo controlled phase II study to evaluate the safety and efficacy of Lucanthon adiminstered as an adjunct to radiation and temozolomide for primary therapy of Glioblastoma Multiforme	II	Globally 140 India 70	1. Dr. Suresh H. Adnavi, Jaslok Hospital and Reseach Centre, Mumbai 2. Dr. Goura Kishor Rath, Dr. Bhim Rao Ambedkar Institute Rotary Cancer Hospital, AIIMS, New Delhi 3. Dr. Govindbabu Kanakashetty, Kidwai Memorial Institute of Oncology, bangalore 4. Dr. Rajiv Ranjan Prasad, Regional cancer center, Indira gandhi Institute of Mediaci sciences, Patna 5. Dr. Malladi Ramakrishna, MNJ Institute of Oncology, Regional cancer Centre, Hyderabad 6. Dr. Naresh Somani, Bhagwan Mahaveer Cancer Hospital and Research center, Jaipur	13-04-12

101	CT/105/10	SH T006581D	91773	Bayer	A multicentre, open, uncontrolled phase III study to investigate the efficacy and safety of a 4-phasic oral contraceptive SH T006581D containing estradiol valerate and dienogest in a 28 day regimen for 13 cycles in healthy female subjects	III		1. Dr. Alka Kriplani, AIIMS, New delhi 2. Dr. R. Anupama, PRS hospital, trivandrum 3. Dr. Ritu Joshi, Monilek hospital and Research Center, Jaipur 4. Dr. Bharti kalra, Bharti Hospital, karnal, haryana 5. Dr. sanjay gupte, Gupte Hospital and Centre for Research in Reproduction, Pune 6. Dr. Vaishali Chavan, Ruby Hall Clinic, Pune	19-04-12
-----	-----------	-------------	-------	-------	--	-----	--	--	----------

102	CT/153/11	Armodafinil	C10953/3074	Inventive	A six month, open label, flexible doses (150-200mg/day) extension study of safety and efficacy of armodafinil treatment as adjuvant therapy in adults with major depression with Bipolar-I disorder	III	Globally-900 India-72	<p>1.Dr. Ranjivi Mahajan, Dayanand Medical college and hospital, Ludhiana, Punjab,</p> <p>2.Dr. Satheesh Rao, KS Hedge Medical academy, Mangalore, Karnataka,</p> <p>3.Dr. Nadukuru Nooka Raju, Maharishi Institute of Neuro-psychological Disorders, Visakhapatnam,</p> <p>4.Dr. Venu Gopal Janwar, Deva Mental Healthcare, Varanasi,UP,</p> <p>5. Dr. Jitendra Kumar Trivedi, Manobal Medical Research Centre,Lucknow, UP</p> <p>6. Dr. (Prof) Priyavadan Chandrakant Shastri, Dr. Shastri clinic, 3/3, Viva co-op Housing Socieity, S.V. Road, Andheri 400058, Maharashtra</p>	7/3/2012
103	CT/70/11	BIBF 1120	1199.32	Boehringer	A 52 weeks, double-blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150mg twice daily, on annual forced vital capacity decline, in patients with Idiopathic Pulmonary Fibrosis (IPF)	III	India -75, Globally-485	<p>1.Dr. T. Mohankumar , Ramakrishna Hospital, Coimbatore</p> <p>2. Dr. K.S. Satish, Chest and Maternity Centre, Banglore,</p> <p>3.Dr. Parag Khatavkar, K.E.M. Hospital, Pune</p> <p>4. Dr. Parmod Niphadkar , Asthma and allergy centre, Mumbai</p> <p>5. Dr. Ashish Kumar, Asthma Bhawan, Jaipur</p> <p>6. Dr. Mahendra Kawedia, Jehangir Clinical Development Centre Pvt. Ltd., Pune</p> <p>7. Dr. Naidu Bethune, Yashoda Super-Speciality Hospital, Hyderabad, Andhra Pradesh</p>	

**BIOLOGICALS**

Sr no	File No	Drug Name	Protocol	Applicant/Sponsor	Title	Phase	Name of investigator and address	No. Of subjects	CT approval date
-------	---------	-----------	----------	-------------------	-------	-------	----------------------------------	-----------------	------------------

1	CT/80/2011-DCGI	MCC Concentrate/EN3348 Mycobacterium Cell Wall DNA	EN3348-303	DIAGNOSEARCH	A Phase 3. Randomized, Active –Controlled, Open –Label, Multicenter Study To Evaluate the Efficacy and Safety of EN3348 (MCC) as compared with Mitomycin C in the Intravesical Treatment of Subjects with BCG Recurrent of Refractory Non-Muscle Invasive Bladder	III	1. Dr. Nayan Kumar Mohanty- V. M. Medical College, Safdarjang Hospital, Sri Aurobindo Marg, New Delhi. 2. Dr. Kalyan Kumar Sarkar - Woodlands medical centre Ltd., 8/5, Alipore road, Kolkata - 700 027. 3. Dr. Bhalchandra Kashyapi - Sahyadri Speciality Hospital, 30 C, Erandwane Karve Road, Pune. 4. Dr. Rajeev Sood	70	17.07.2012
---	-----------------	--	------------	--------------	--	-----	--	----	------------

2	CT/135/ 2011- DCGI	Velaglycerase Alfa (VPRIV)	HGT- GCB-068	Quintiles Research	Multicenter open label efficacy and safety study of velaglucerase alfa enzyme replacement therapy in children and adolescent with type 3 gaucher disease	I/II	6	17.04.2012
---	--------------------------	-------------------------------	-----------------	-----------------------	---	------	---	------------

3	CT/172/ 2011- DCGI	GP 2013	GP13-301	PPD	A randomized, Controlled, Double-Blind Phase III Trial to compare the efficacy, safety and Pharmacokinetics of GP2013 plus CVP vs. MebThera® plus CVP followed by GP2013 or MebThera® maintenance therapy in patients with previously untreated, Advanced stage Follicular Lymphoma	III	1. Dr. Chetan Deshmukh - Deenanth Mangeshkar Hospital and Research Centre, Pune. 2. Dr. Lokanatha Dasapa, Kidwai Memorial Institute of Oncology, Bangalore. 3. Dr.	120	17.04.2012
---	--------------------------	---------	----------	-----	---	-----	--	-----	------------

4	CT/185/ 2011- DCGI	Trastuzu mab-MCC- DM1 (T- DM1 Trastuzu mab)	BO25734	Roche Products	A Phase III randomized multicenter two arm open label trial to evaluate the efficacy of TDM 1 compared with treatment of physician choice in patients with HER -2 positive metastaic breast cancer who have received atleast two prior regimen of HER- 2 direct therapy under F.Hoffmann La roche limited	III	1. Dr. Ajai Kumar - Bangalor e Institute of Oncolog y, Triesta Sciences, Bangalor e. 2. Dr. D.C.Dova l - Rajiv Gandhi Cancer Institute and Research Centre, Delhi. 3. Dr. Shona Nag - Sahyadri Specialit	9	17.04.2012
---	--------------------------	--	---------	-------------------	---	-----	--	---	------------

5	CT/194/ 2011- DCGI	Denosumab (AMG 162)	20080560	Amgen	A double blind, placebo-controlled, study to evaluate New or Worsening Lens Opacifications in subjects with Non-metastatic Prostate Cancer Receiving Denosumab for bone loss due to Androgen-Deviation Therapy	III	1. Dr. Rajnish Magarkar - Cuire Manavat a Caner Centre, Nasik. 2. Dr. Kirushna Kumar - Meenakshi Mission Hospital & Research Centre, Madurai. 3. Dr. Srinivasan Krishnan - Dr. Rai Memorial Medical Centre,	65	16.04.2012
---	--------------------------	---------------------	----------	-------	--	-----	---	----	------------

6	CT/195/11-DCGI	EMOCLOT	KB053	Max Neeman	Open Label, Phase III, Multicenter study on Pharmacokinetic, Efficacy, and safety Evaluation of Kedrion Factor VIII Concentrate (EMOCLOT) in 50 Previously Treated Hemophilia A Children	III	1.Dr. Cecil Ross - St. John's Medical College & Hospital, Bangalore Karnataka. 2.Dr. Shashikant Apte - Sahyadri Speciality Hospital, Pune. 3.Dr. Vijay Ramana - Jehangir Clinical Develop	60	16.04.2012
---	----------------	---------	-------	------------	--	-----	---	----	------------

7	CT/217/11-DCGI	, Human Coagulation Factor IX Fusion Protein (rFIXFc)	9HB01EXT	Biogen Idec	An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant, Long-Acting, <u>Human Coagulation Factor IX Fusion Protein (rFIXFc)</u> in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B	III	1. Dr. Shashikant Apte - Sahyadri Speciality Hospital, Pune. 2. Dr. Cecil Ross - St. John's Medical College Hospital, Bangalore. 3. Dr. Alok Srivastava - Christian Medical College, Vellore.	15	23.04.2012
---	----------------	---	----------	-------------	--	-----	---	----	------------

8	CT/218/ 11- DCGI	Ofatumumab, (GSK1841 157)	OMB 110928	GSK	Ofatumumab versus Rituximab Salvage Chemoimmunot herapy followed by ASCT in Relapsed or Refractory DLBCL	III	10	1. Dr. Vijay Ramana n - Jehangir Clinical Develop ment Centre, Jehangir Hospital Premises , Pune. 2. Dr. Chetan Deshmu kh - Consulta nt Medical Oncologi st Deenana th Mangesh kar Hospital,	17.04.2012
---	------------------------	---------------------------------	---------------	-----	---	-----	----	--	------------

9	CT/200/11-DCGI	recombinant coagulation Factor IX Fc Fusion Protein, BIIB029	9HB02PED	Biogen Idec	An Open-Label, Multicenter Evaluation of safety, Pharmacokinetics and efficacy of <u>recombinant coagulation Factor IX Fc Fusion Protein, BIIB029</u> in the prevention and treatment of Bleeding Episodes in Pediatric subjects with Hemophilia B	III	1. Dr. Alok Srivastava - Christian Medical College, Vellore. 2. Dr. Anirudh Apte - Sahyadri speciality Hospital, Pune. 3. Dr. Naresh Gupta - Haemophilia Day Care Centre, Maulana Azad Medical College and Lok	10	17.04.2012
---	----------------	--	----------	-------------	--	-----	--	----	------------

10	CT/32/2011-DCGI	Monoclonal antibody isotype IgG2 Panitumumab (Vectibix)	20100007	Amgen	A Phase III multicenter randomized open label trial to evaluate the survival benefit of panitumumab best supportive care, compared to to best supportive care alone in subjects with chemorefractory wild type KRAS metastatic colorectal cancer	III	1. Dr. Shailesh Bondard e - Shatabdi Superspeciality Hospital, Nasik. 2. Dr. Rajinish Nagarkar - Curie Manavata Cancer Centre , Nasik. 3. Dr. Nalini Kilara - MS Ramaiah Curie Centre of OnCology,	55		30.01.2012
----	-----------------	---	----------	-------	--	-----	--	----	--	------------

11	CT/60/2 011- DCGI	V212- Inactivate d Varicella Zoster Virus Vaccine	011-00	MSD	A Phase III, Randomized, Placebo controlled, Clinical trial to study safety and efficacy of V212 in Adult patients with solid Tumor or Hematologic Malignancy	III	1. Dr. Minish Jain - Medical Oncologi st, Ruby Hall Clinic, Pune. 2. Dr. Rajinish Nagarkar - Curie Manavat a Cancer Centre , Nasik. 3. Dr. D. Lokanath a - Kidwai Menorial Institute of Oncolog y, Bangalor	300	18.04.2012
----	-------------------------	---	--------	-----	--	-----	---	-----	------------

12	CT/154/ 2011- DCGI	SAR15319 1	EFC1107 2	Sanofi	A Phase III Randomized, double-blind, placebo-controlled, multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of SAR153191 on top methotrexate (MTX) in patients with active rheumatoid arthritis who are inadequate responders to MTX therapy"	III	125 1.Dr. Banwari Sharma - Jaipur Hospital, Jaipur. 2.Dr. v. Krishna murthy - Chennai Meenakshi Multispecialty Hospital, Chennai. 3.Dr. Rajiva Gupta - Medanta - the Medicity , Haryana. 4.Dr. Chandra sekhar	01.05.2012
----	--------------------------	---------------	--------------	--------	--	-----	---	------------

13	CT/197/2011-DCGI	Teriparatide (rDNA origin) Injection (LY333334)	B3D-MC-GHDN(a)	M/s Eli Lilly and Company (India) Pvt Ltd, Plot No. 92, Sector 32, Gurgaon-122001	A phase III Prospective, randomized, parallel, double blind, placebo-controlled, multi-center, multinational study with a 6 month double blind treatment period followed by an 18 months observation period. This study will compare <b>teriparatide</b> 20 µg/day versus placebo on successful fracture healing in men and postmenopausal women ≥50 years of age after a low trauma femoral neck fracture	III	1. Dr. K.J. Reddy - Apollo Hospitals, Hyderabad, A.P. - 500033. 2. Dr. Krishna Kiran Eachempati - Krishna Institute of Medical Sciences. Secunderabad, Hyderabad, A.P. 500003. 3. Dr. Sushrut Bhadulka	75	25.07.2012
----	------------------	---	----------------	---	--	-----	--	----	------------

14	CT/229/11-DCGI	Teriparatide (rDNA origin) Injection (LY333334)	B3D-MC-GHDQ	M/s Eli Lilly and Company (India) Pvt Ltd, Plot No. 92, Sector 32, Gurgaon-122001	A phase III Prospective, randomized, parallel, double blind, placebo-controlled, multi-center, multinational study with a 6 month double blind treatment period followed by an 18 months observation period. This study will compare teriparatide 20 µg/day versus placebo on successful fracture healing in men and postmenopausal women ≥50 years of age	III	1. Dr. Sanov Bagchi - AMRI Hospitals Gariahat Road Kolkata - 700029. 2. Dr. Harish Chandra n-Cosmopolitan Hospitals Pvt Ltd Pattom Trivandrum, Kerala. 3. Dr. Naresh Shetty - Deptt. Of Orthopaedics	75	25.07.2012
----	----------------	---	-------------	---	--	-----	--	----	------------

15	CT/72/2011-DCGI	MEDI-545 (Sifalimumab)	CD-IA-MEDI-545-1067/D2800L00004	AstraZeneca	A Phase II b, Dose-ranging study to evaluate the efficacy and safety of Sifalimumab in Adults with Systemic Lupus Erythematosus	II b	<p>1. DR. Liza Rajaashekar - Nizam Institute of Medical Science, Hyderabad.</p> <p>2. Dr. Mathews Thomas - Health and Research Centre, Trivandrum, Kerala.</p> <p>3. Dr. Sarath Chandra Mouli Veeerav</p>	32	23.04.2012
----	-----------------	------------------------	---------------------------------	-------------	---	------	---	----	------------

16	CT/176/ 2011- DCGI	A-623 (Blisibimod)	AN- SLE3322	Kendle	An open label long term safety extension trial for subjects with systemic lupus erythematosus who have completed protocol An -sle-3321	II	1.Dr. Anjali Rajadhya ksha - Seth G.S. Medical College & King Edward Memorial Hospital, Parel, Mumbai 400012. 2.Dr. Sarath C Veeravalli Krishna Institute of Medical Sciences Ltd, Hyderabad. 3.Dr.	51	07.05.2012
----	--------------------------	-----------------------	----------------	--------	--	----	---	----	------------

17	CT/212/11-DCGI	NT201	MRZ60201/SP/3001	Kendle	Prospective, double blind, placebo-controlled, randomized, multi-center study with an open label extension period to investigate the efficacy and safety of NT 201 in the treatment of Post-stroke spasticity of upper limb	III	1.Dr. Mohit Bhatt - Kokilaben Dhirubhai Ambani & Medical Research Institute, Mumbai. 2.Dr. Madhuri Behari - AIIMS, New Delhi. 3.Dr. C.U. Velmurgendran-Sri Ramchandra Medical Centre,	75		07.05.2012
----	----------------	-------	------------------	--------	---	-----	---	----	--	------------

18	CT/201/11-DCG(I)	Daclizumab High Yield Process (DAC HYP)	205MS203	Biogen Idec	A Phase 2b, A Multicentre , Open –label , Extension Study to Evaluate the Long-term Safety and Efficacy of Daclizumab High Yield process (DAC HYP) Monotherapy in Subjects with Multiple Sclerosis who have completed Treatment in study 205MS202 (SELECTION)	II b	1. Dr. Rajram Agarwal - Fortis Escorts Hospital, Jaipur. 2. Dr. Pahari Ghosh - Sri Aurbindo Seva Kendra, Kolkata. 3. Dr. Thomas Mathew - St. John's Medical College Hospital, Department of Neurology, Bangalor	11	07.05.2012
----	------------------	---	----------	-------------	---	------	---	----	------------

19	CT/148/ 11- DCGI	Denosumab (Immunoglobulin G2 Human Mucosal Antibody to RANK ligand)	20110113	Amgen	Open label access protocol of denosumab for subject with advanced cancer.	III b	1. Dr Subhashi ni John : Professo r in Radiothe rapy Christian Medical College IDA Scudder Road, Departm ent of Radiatio n Oncolog y Vellore - 632004 Tamilnad u. 2. Dr. Anish Maru Sr Consult ant	2		13.06.2012
----	------------------------	---	----------	-------	--	-------	--	---	--	------------

20	CT/236/ 11- DCGI	Pertuzum ab	MO27775	Roche Products	A randomized, two-arm, open-label, multicenter Phase II trial assessing the efficacy and safety of Pertuzumab given in combination with Trastuzumab plus an aromatase inhibitor in first line patients with HER2-positive and hormone receptor-positive advanced (metastatic or locally advanced) Breast cancer	II	1. Dr.Minish Jain - Ruby Hall Clinic, New Cancer Centre, Pune. 2. Dr. P.K. Das - Indraprastha Apollo Hospitals, New Delhi. 3. Dr. Suresh Advani - Jaslok Hospital & Research Centre, Maharas	35	25.07.2012
----	------------------------	----------------	---------	-------------------	---	----	--	----	------------

21	CT/232/ 11- DCGI	(rFVIII Fc) Recombinant Human Coagulation Factor VIII Fusion Protein.	8HA01E XT	Biogen Idec	An Open- Label, Multicenter Evaluation of the Long Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIII Fc) in the Prevention and Treatment of Bleeding Episodes in Previously treated Subjects with Hemophilia A	III	1. Dr. Cecil Ross - St. John's Medical College Hospital, Bangalore. 2. Dr. Alok Srivastava - Christian Medical College, Vellore. 3. Dr. Shashikant Apte - Sahyadri Speciality Hospital, Pune. 4. Dr. Joseph	25	13.06.2012
----	------------------------	---	--------------	----------------	--	-----	---	----	------------

22	CT/230/ 11- DCGI	OPT-822	OPT-822- 001	Clinigene	A Double Blind,Randomiz ed, Phase II/III trail of active immunotherapy with Globo H- KLH(OPT-822) in subjects with Metastaic Breast Cancer	II/III	1. Dr. SVSS Prasad - Apollo Hospital, Hyderab ad. 2. Dr. Sameer Khatri - HCG SMH Curie Centre, Delhi	80	11.06.2012
----	------------------------	---------	-----------------	-----------	---	--------	--	----	------------

23	CT/32/2012-DCGI	Recobinant Factor IX (rFIX)	251101	BAXTER	A phase 2/3 prospective, uncontrolled, multicenter study evaluating pharmacokinetics, efficacy, safety, and immunogenicity in previously treated pediatric patients with severe (FIX LEVEL<1%) or moderately severe (FIX LEVEL< 2%) Hemophilia B	II/III	<p>1. Dr. Sahshikant Apte - Sahayadri Specialty Hospital, Pune.</p> <p>2. Dr. Naresh Gupta - LNJP Maulana Azad Medical College &amp; associated Hospitals New Delhi.</p> <p>3. Dr. Vijay Ramana Madatha</p>	6		12.06.2012
----	-----------------	-----------------------------	--------	--------	--	--------	---	---	--	------------

24	CT/235/ 11- DCGI	Rindopepimunt (CDX110)	CDX110- 04	Novotech	An International, randomized, double-blind, Controlled study of Rindopepimut/G M-CSF with Adjuvant Temozolomide in patients with newly Diagnosed, Surgically Resected, EGFRvIII-Positive Glioblastoma (The ACT IV Study)	III	1.Dr. Dilip Panikar - Professor and Head of Department of Neurosurgery, Amrita Institute for Medical Sciences, Cochin , Kerala 2.Dr. Suresh Nair - Professor, Senior Grade & Head, Department of Neurosurgery	53	12.06.2012
----	------------------------	---------------------------	---------------	----------	--	-----	--	----	------------

25	CT/317/ 10- DCGI	THR -18	THR- 2010-01	Infinitus	Double Blind, placebo controlled, escalating single- dose, pilot study to assess the safety and efficacy of THR- 18 when administered to patients suffering acute ischemic stroke and treated with tPA	II a	1. Dr. Gosala Raja Kukkuta Sarma - St. John's Medical College Hospital, Bangalore. 2. Rajesh Shetty - Neuro Clinic, Mangalore.	10	28.08.2012
----	------------------------	---------	-----------------	-----------	--	------	--	----	------------

26	CT/69/12-DCGI	VGX-3100	HPV-003	Max Neeman	Phase II Placebo-Controlled study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) delivered IM followed by Electroporation (EP) with CELLECTRA®-5P for the treatment of biopsy- proven CIN 2/3 or CIN 3 with documented HPV 16 or 18”	II	1.Dr. Chetan Deshmukh - Deenanth Mangeshkar Hospital and Research Center, Pune. 2. Dr. Ranu Patni - Apex Hospital, Jaipur. 3. Dr. Seetha Panicker - PSG Institute of Medical Sciences,	50	27.08.2012
----	---------------	----------	---------	------------	---	----	--	----	------------

27	CT/71/11-DCGI	Lapatinib Ditosylate Monohydrate (GW572016 Ditosylate Monohydrate)	UM2010/00099/00	GlaxoSmithkline	<p>A Phase III trial to compare the safety and efficacy of <b><u>lapatinib plus an aromatase (AI)</u></b> Versus transtuzumab plus an AI Versus lapatinib plus an AI as first line therapy in postmenopausal subjects with hormone receptor positive, HER2-positive metastatic breast cancer who have received transtuzumab and endocrine therapy in the neoadjuvant and/or adjuvant setting.</p>	III	<p>1. Dr. Dinesh Doval - Rajiv Gandhi Cancer Institute and research centre, New Delhi.  2. Dr. Ajay Mehta - Central India Cancer Research Institute, Nagpur.  3. Dr. Manish Jain - Ruby Hall Clinic,</p>	75	07.09.2012
----	---------------	--	-----------------	-----------------	---	-----	--	----	------------

28	CT/57/12-DCGI	BCD-020 (rituximab)	BIORIX	M/s SMO Clinical Research (I) Pvt. Ltd., 335,14th Main, Sadaahiva Nagar, RMV Extension, Bangalore-560080	A multicenter, open-label, randomized study of <b><u>BCD-020 (rituximab,</u></b> CJSC BIOCAD, Russia) efficacy and safety in comparison with MabThera® (F. Hoffmann-La Roche Ltd., Switzerland) in monotherapy of CD 20- positive indolent non-Hodgkin Lymphoma”	III	1.Dr. Cecil Ross - St. John's Medical College & Hospital, Bangalore Karnataka. 2.Dr. Chetan Deshmukh - Deenanth Mangeshkar Hospital and Research Centre, Pune. 3.Dr. Shekar	14	06.09.2012
----	---------------	---------------------	--------	--	--	-----	---	----	------------

29	CT/14/12-DCGI	LA - EP2006	LA-EP06-302	M/s InVentiv International Pharma Services, B-101, Hamilton, hiranandani Business Park, Ghodbunder Road, Thane (West), Mumbai-400607.	Pivotal study in breast cancer patients investigating efficacy and safety of <u>LA-EP2006</u> and Neulasta®	III	1. Dr. Mamilal palli Gopichand - City Cancer Centre, Vijaywada. 2. Dr. Venkata Satya Suresh Attili - BIBI General Hospital & Cancer Centre, Hyderabad. 3. Dr. Chairmana Haritha - M.S. Patel	150	06.09.2012
----	---------------	-------------	-------------	---	---	-----	--	-----	------------

30	CT/16/12-DCGI	LA - EP2006	LA-EP06-301	M/s InVentiv International Pharma Services,	A randomized, double blind, parallel group, multi-center Phase 3 comparative study investigating efficacy and safety of <b>LA-EP2006</b> and Neulasta® in breast cancer patients treated with established myelosuppressive chemotherapy	III	1. Dr. Mamilapalli Gopinath - City Cancer Centre, Vijaywada. 2. Dr. Venkata Satya Suresh Attili - BIBI General Hospital & Cancer Centre, Hyderabad. 3. Dr. Chairmana Haritha - M.S. Patel	150	10.09.2012
----	---------------	-------------	-------------	---	---	-----	---	-----	------------

31	CT/60/2012	biphasic insulin aspart (BIAsp)	BIAsp3963	Novo Nordisk	A phase IV study titled "A 24 week randomized, open label, 3 parallel –group comparison of once and twice daily biphasic insulin aspart (BIAsp) 30 plus sitagliptin and twice daily BIAsp 30, all in combination with metformin in insulin naïve type 2 diabetic subjects inadequately controlled on sitagliptin and metformin	IV	<p>1. Dr. Anuradha - Diabetomics India pvt Ltd, Hyderabad ad.</p> <p>2. Dr. Jayanthi Ramesh - # 8-2-626/B, Krishna Athreya Road No 11 Hyderabad ad.</p> <p>3. Dr. Prof. Debasish Maji - Calcutta Diabetes and</p>	200	01.10.2012
----	------------	---------------------------------	-----------	--------------	--	----	---	-----	------------

32	CT/75/12	Insulin Degludec /liraglutide & Insulin Degludec (Ideg)	NN9068-3951	Novo Nordisk	A Phase III b Clinical trial titled "The efficacy of insulin degludec/liraglutide as add-on therapy in controlling glycaemia in adults with type 2 diabetes inadequately controlled on sulphonylurea with or without metformin therapy	III b	1. Dr. Paramesh Shamanna - Bangalore Clinisearch, Bangalore. 2. Dr. Neeta R Deshpande - Belgaum Diabetes Centre, Karnataka. 3. Dr. Nikhil M Bhagawat - BYL Nair Hospital and T N	100	01.10.2012
----	----------	---	-------------	--------------	--	-------	--	-----	------------

33	CT/81/12-DCGI	Liraglutide 6 mg/ml (Victoza)	NN2211-3917	Novo Nordisk	A 26 week double –blind placebo –controlled randomized multicenter, multinational parallel -group trial to study the effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes.	III b	1. Dr. S.K. Sharma - Diabetes Thyroid and Endocrine Centre Jaipur. 2. Dr. Anibran Majumdar - Gariahat Road South Dhakuria West Bengal. 3. Dr. Sudip Chatterji - Park Clinic Gorkey Terrace, West Bengal. 4. Dr. S...	90	19.10.2012
----	---------------	-------------------------------	-------------	--------------	---	-------	---	----	------------

34	CT/202/11-DCGI	BA058	BA058-05003	Pharmanet	A randomized, double blind, placebo-controlled, comparative Phase III Multicenter study to evaluate safety and efficacy of BA058 for injection for prevention of fracture in ambulatory postmenopausal women with severe osteoporosis and at risk of fracture	III	1. Dr. K.M. Prasanna Kumar - Bangalore Diabetes Hospital, Bangalore. 2. Dr. Sanjay Reddy - Medisys Clinsearch India Pvt Ltc, Bangalore. 3. Dr. Dinakar Rai - PSG Hospitals, Coimbatore. 4. Dr.	200	01.10.2012
----	----------------	-------	-------------	-----------	---	-----	---	-----	------------

35	CT/41/2012-DCGI	AMG 785 & Denosumab	20070337	Amgen	A Phase III study entitled "A multicenter, International Randomized, Double Blind Placebo Controlled, Parallel group study to Assess the efficacy and safety of AMG 785 treatment in Postmenopausal women with Osteoporosis	III	1. Dr. Usha Sriram - ACCER/Associates in clinical Endocrinology and Research, Adyar, Chennai. 2. Dr. Nares h Shetty - Medical College and Hospital, Bangalore. 3. Dr. Nalini shah - Seth G.S. Medical College	110	01.10.2012
----	-----------------	---------------------	----------	-------	---	-----	---	-----	------------

36	CT/84/12-DCGI	Recombinant factor IX (rFIX)	251002	BAXTER	A Phase 3 Prospective, Multicenter Study Evaluating Efficacy and Safety in Previously Treated Patients with Severe (FIX level < 1%) or Moderately Severe (FIX level ≤ 2%) Hemophilia B Undergoing Surgical or Other Invasive Procedures.	III	1. Dr. Shashikant Janardhan Apte, Sahayadri Speciality Hospital, Pune 2. Dr. Naresh Gupta, LNJP Maulana Azad Medical College & Associated Hospital, New Delhi. 3. Dr. Vijay Ramanan, Jehangir Hospital and Research	15	28.12.2012
----	---------------	------------------------------	--------	--------	--	-----	---	----	------------

37	CT/103/ 12- DCGI	Recombinant factor IX (rFIX)	251001	BAXTER	BAX326 (Recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients with Severe (FIX level < 1%) or Moderately Severe (FIX level ≤ 2%) Hemophilia B – A Continuation Study	III	1. Dr. Shashikant Janardhan Apte, Sahayadri Speciality Hospital, Pune 2. Dr. Naresh Gupta, LNJP Maulana Azad Medical College & Associated Hospital, New Delhi. 3. Dr. Vijay Ramanan, Jehangir Hospital and Research	6	28.12.2012
----	------------------------	------------------------------	--------	--------	---	-----	---	---	------------

38	CT/87/1 2-DCGI	Tenofovir Disoproxil Fumarate	GS-US- 174-0149	Klinera	A Phase 4 Randomized open label active controlled Superiority study to evaluate the efficacy and safety of Tenofovir Disoproxil Fumarate (TDF) in combination with Peginterferon alfa 2 a (Pegasys) versus standard of care Tenofovir Disoproxil Fumarate Monotherapy or peginterferon alfa 2 a Monotherapy for 48 weeks in non cirrhotic subjects with HbeAg positive or HbeAg	IV	1. Dr. Rajiv Manhar Mehta - Liver Clinic, Surat Gujrat. 2. Dr. Shobna Bhatia - Seth G.S. Medical Collge and KEM Hospital, Mumbai. 3. Dr. Abjiji Chowdh ury - Institute of Post Graduat e Medical Educatio	200	18.10.2012
----	-------------------	-------------------------------------	--------------------	---------	---	----	---	-----	------------

39	CT/58/12-DCGI	MEDI-546	CA-IA-MEDI-546-1013	Kendle	A phase 2, Randomized study to evaluate the efficacy and safety of MEDI-546 in subjects with systemic lupus erythematosus.	II	1 Dr. Sarath Chandra Mouli Veeravail - Krishna Institute of Medical Sciences Ltd. Andhra Pradesh. 2. Dr. A. G. Rajadhya Ksha-Department of Medicine Seth GS Medical College and KEM Hospital Parel, Mumbai. 3. Dr. Vineeta Shobha -	50	26.11.2012
----	---------------	----------	---------------------	--------	--	----	---	----	------------

40	CT/66/1 2-DCGI	Sevuparin- /DF02	TSM03	Max Neeman	Low anticoagulant heparin (sevuparin/DF02 ) as adjunctive therapy in moderate to severe P. falciparum malaria. A phase II single-centre, randomized, placebo- controlled, double blind study”	II	1. Dr. Saroj Mishra - Departm ent of Medicine ISPAT General Hospital Rourkela 769005, Odisha	20	12.11.2012
----	-------------------	---------------------	-------	---------------	--	----	---	----	------------

41	CT/145/ 2011- DCGI	Insulin Degludec /liraglutid e	NN9068- 3912	Novo Nordisk	A Phase III trial – “ A 26 week Randomized, Parallel, Two Arm, Double - Blind, Multicenter, Multinational, Treat- to – Target trial comparing fixed ratio combination of Insulin Degludec and Liraglutide with insulin Degludec in subjects with type 2 Diabetes	III	1. Dr. Satish Pitale- Pit ale Diabetes and Hormon e Centre, Nagpur. 2. Dr. Ghanshy anm Goyal- H.S. Hospital, Jeewans atya, Kolkatta. 3. Dr. Shehla saikh - KGN Diabetet s and Endocrin ology Centre,	20	20.01.2012
----	--------------------------	---	-----------------	-----------------	--	-----	--	----	------------

42	CT/171/ 2011- DCGI	B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1)	1-301	Max Neeman	Phase III trial to find efficacy and safety of B-Doain deleted recombinant procin factor VIII in the treatment of acquired hemophilia A due to factor VIII inhibitory auto -antibody.	III	1. Dr. Revathi Raj - Apollo Speciality Hospital, Chennai, Tamil Nadu. 2. Dr. Raghuvier Prabhu - Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala.	10	05.03.2012
----	--------------------------	--	-------	------------	---	-----	---	----	------------